enchanted_elixir
𝕸𝖊𝖗𝖈𝖊𝖓𝖆𝖗𝖞 𝕮𝖔𝖗𝖕 • 𝟐𝟎𝟐𝟐🥉
Contributor
- Joined
- Apr 15, 2022
- Posts
- 24,374
- Reputation
- 43,404
THE COMPLETE NOOTROPICS MASTERCLASS
VOLUME 3: THE LIST OF COMPOUNDS
PART 5 OF 11 | CATECHOLAMINERGIC ACTIVITY, DOPAMINE RECEPTORS & MONOAMINE CONTROL
VOLUME 3: THE LIST OF COMPOUNDS
PART 5 OF 11 | CATECHOLAMINERGIC ACTIVITY, DOPAMINE RECEPTORS & MONOAMINE CONTROL
21.5 Catecholaminergic Activity Enhancers
21.5.1 Phenylpropylaminopentane / PPAP — Making Active Circuits Release a Larger Signal
What it is: PPAP—1-phenyl-2-propylaminopentane, also called α,N-dipropylphenethylamine—is an experimental selegiline-derived catecholaminergic activity enhancer. It has extensive preclinical mechanism discussion and essentially no modern controlled human efficacy, dose-finding, or pharmacokinetic program.
What it may feel like: PPAP may feel unimpressive while you sit idle. Once you begin research, exercise, conversation, writing, gaming, sex, or another engaging activity, the activity can become more rewarding and easier to continue. It does not reliably choose the useful target: productive work can acquire momentum, but so can scrolling, arguing, compulsive optimization, or any other behavior already generating catecholamine signals. Other reports describe a mild ordinary stimulant, anxiety, visual changes, hyperreflexia in stacks, or no effect.
The simplest description: Imagine a microphone amplifier. PPAP does not necessarily create the speaker’s voice; it may make each existing word louder. A quiet neuron gives it little to amplify. An actively firing catecholamine circuit may release more signal than it otherwise would.
How It Works
Foundational experiments describe PPAP entering catecholamine terminals and enhancing impulse-propagation-mediated dopamine and norepinephrine release without the uncontrolled resting transmitter release characteristic of amphetamine. It has little MAO-inhibitory activity and is not simply selegiline under another name. Later transporter and trace-amine work suggests that the old “pure enhancer” story may be incomplete.
This mechanism is why activity dependence matters in real life: another stimulant can increase neuronal firing and give PPAP more signal to amplify. It is not an interaction shield or a guarantee of intelligent motivation. Animal behavior implies CNS exposure, but human BBB penetration and central-versus-peripheral selectivity are unquantified.
Dose and How It Was Studied
There is no validated human studied or labeled dose, although in my experience 25mg is a good dose. Forum reports often discuss amounts in the tens of milligrams, sometimes much more, but those are unblinded exposures to uncertain material and are not dose-finding evidence. Animal milligrams per kilogram cannot be converted into a safe human amount by simple arithmetic.
The HCl salt and free base have different solubility and handling. An amine salt may dissolve in water more readily, while the free base may not; public formulation-grade water, lipid, pH, stability, and tissue-irritation data remain inadequate. Reports of caustic sublingual or intranasal material are a warning, not an administration technique. There is no validated fasting, fat, solvent, or route rule.
Timing and Pharmacokinetics
Evidence and Experiences
Evidence is preclinical. It supports an interesting category of impulse-dependent release enhancement, but does not establish improved grades, ADHD treatment, healthy cognition, cardiovascular safety, or a therapeutic window. There is no approved clinical indication.
Anecdotes often make the activity dependence vivid. Users describe needing to begin something mentally or physically challenging before the “ball starts rolling,” activity becoming more rewarding and streamlined, or PPAP potentiating caffeine and prescription stimulants. Negative reports describe excessive anxiety, visual effects, strong stimulant-like action at higher alleged amounts, hyperreflexia, and uncertain withdrawal. Activity-dependent account · Reward-and-momentum description · Recent mixed safety discussion
Safety, Interactions, and Monitoring
Human adverse-effect incidence is unknown. Plausible and reported problems include anxiety, agitation, insomnia, headache, appetite change, visual disturbance, hyperreflexia, tachycardia, hypertension, and compulsive engagement. Seek urgent care for chest pain, fainting, severe or irregular heartbeat, marked hypertension, hyperthermia, confusion, seizure, hallucinations, mania, or prolonged sleeplessness.
Assume potentially dangerous amplification with MAO inhibitors, amphetamines, methylphenidate, bupropion, modafinil, bromantane, levodopa, dopamine agonists, decongestants, and other monoaminergic compounds. “Activity-dependent” may make combinations more, not less, consequential because the other drug supplies activity to amplify.
Tolerance, receptor adaptation, dependence, withdrawal, and a safe cycle are unknown. Chemically amplified reward can train psychological reliance even without forced resting release. Pregnancy, breastfeeding, minors, cardiovascular disease, seizure history, bipolar disorder, psychosis, severe anxiety, and substance-use vulnerability have no established safe-use basis.
Formal monitoring would include verified stereoisomer/salt/batch, pulse, blood pressure, temperature, sleep, appetite, anxiety, mood elevation, task choice, time-on-task, error rate, compulsive behavior, and performance after stopping. Independent LC-MS identity, assay, impurity and residual-solvent testing are prerequisites for interpretable research.
Bottom Line
PPAP has one of the most intuitive and seductive mechanisms in the guide: it may amplify the motivation signal generated by what you are already doing. That is not the same as safe, selective, or smart motivation. With no human PK, dose-finding, efficacy trial, or long-term safety program, the mechanism remains a research hypothesis surrounded by vivid but unquantifiable anecdotes.
What it is: PPAP—1-phenyl-2-propylaminopentane, also called α,N-dipropylphenethylamine—is an experimental selegiline-derived catecholaminergic activity enhancer. It has extensive preclinical mechanism discussion and essentially no modern controlled human efficacy, dose-finding, or pharmacokinetic program.
What it may feel like: PPAP may feel unimpressive while you sit idle. Once you begin research, exercise, conversation, writing, gaming, sex, or another engaging activity, the activity can become more rewarding and easier to continue. It does not reliably choose the useful target: productive work can acquire momentum, but so can scrolling, arguing, compulsive optimization, or any other behavior already generating catecholamine signals. Other reports describe a mild ordinary stimulant, anxiety, visual changes, hyperreflexia in stacks, or no effect.
The simplest description: Imagine a microphone amplifier. PPAP does not necessarily create the speaker’s voice; it may make each existing word louder. A quiet neuron gives it little to amplify. An actively firing catecholamine circuit may release more signal than it otherwise would.
How It Works
Foundational experiments describe PPAP entering catecholamine terminals and enhancing impulse-propagation-mediated dopamine and norepinephrine release without the uncontrolled resting transmitter release characteristic of amphetamine. It has little MAO-inhibitory activity and is not simply selegiline under another name. Later transporter and trace-amine work suggests that the old “pure enhancer” story may be incomplete.
This mechanism is why activity dependence matters in real life: another stimulant can increase neuronal firing and give PPAP more signal to amplify. It is not an interaction shield or a guarantee of intelligent motivation. Animal behavior implies CNS exposure, but human BBB penetration and central-versus-peripheral selectivity are unquantified.
Dose and How It Was Studied
There is no validated human studied or labeled dose, although in my experience 25mg is a good dose. Forum reports often discuss amounts in the tens of milligrams, sometimes much more, but those are unblinded exposures to uncertain material and are not dose-finding evidence. Animal milligrams per kilogram cannot be converted into a safe human amount by simple arithmetic.
The HCl salt and free base have different solubility and handling. An amine salt may dissolve in water more readily, while the free base may not; public formulation-grade water, lipid, pH, stability, and tissue-irritation data remain inadequate. Reports of caustic sublingual or intranasal material are a warning, not an administration technique. There is no validated fasting, fat, solvent, or route rule.
Timing and Pharmacokinetics
- Subjective onset: Anecdotally 30–120 minutes, sometimes only after activity begins.
- Pharmacologic onset: Unknown in humans; the proposed effect begins when relevant neurons fire in the presence of active compound.
- Tmax: Unknown in humans.
- Absorption/bioavailability: Human oral absorption and absolute bioavailability are not adequately characterized.
- Full practical effect: Unknown and activity-dependent in the anecdotal model; a plasma peak may not predict the moment an engaging task becomes self-propelling.
- Subjective duration: Reports range from a few hours to most of a day.
- Half-life: Human parent and active-effect half-lives are unknown.
- Accumulation/steady state: Unknown; repeated dosing cannot be modeled responsibly.
- Near-complete elimination: No defensible numerical washout exists without parent/metabolite kinetics.
- Metabolism/elimination: Human enzymes, active metabolites, and renal-versus-biliary elimination remain insufficiently mapped; structural relation to selegiline does not prove amphetamine-metabolite formation.
Evidence and Experiences
Evidence is preclinical. It supports an interesting category of impulse-dependent release enhancement, but does not establish improved grades, ADHD treatment, healthy cognition, cardiovascular safety, or a therapeutic window. There is no approved clinical indication.
Anecdotes often make the activity dependence vivid. Users describe needing to begin something mentally or physically challenging before the “ball starts rolling,” activity becoming more rewarding and streamlined, or PPAP potentiating caffeine and prescription stimulants. Negative reports describe excessive anxiety, visual effects, strong stimulant-like action at higher alleged amounts, hyperreflexia, and uncertain withdrawal. Activity-dependent account · Reward-and-momentum description · Recent mixed safety discussion
Safety, Interactions, and Monitoring
Human adverse-effect incidence is unknown. Plausible and reported problems include anxiety, agitation, insomnia, headache, appetite change, visual disturbance, hyperreflexia, tachycardia, hypertension, and compulsive engagement. Seek urgent care for chest pain, fainting, severe or irregular heartbeat, marked hypertension, hyperthermia, confusion, seizure, hallucinations, mania, or prolonged sleeplessness.
Assume potentially dangerous amplification with MAO inhibitors, amphetamines, methylphenidate, bupropion, modafinil, bromantane, levodopa, dopamine agonists, decongestants, and other monoaminergic compounds. “Activity-dependent” may make combinations more, not less, consequential because the other drug supplies activity to amplify.
Tolerance, receptor adaptation, dependence, withdrawal, and a safe cycle are unknown. Chemically amplified reward can train psychological reliance even without forced resting release. Pregnancy, breastfeeding, minors, cardiovascular disease, seizure history, bipolar disorder, psychosis, severe anxiety, and substance-use vulnerability have no established safe-use basis.
Formal monitoring would include verified stereoisomer/salt/batch, pulse, blood pressure, temperature, sleep, appetite, anxiety, mood elevation, task choice, time-on-task, error rate, compulsive behavior, and performance after stopping. Independent LC-MS identity, assay, impurity and residual-solvent testing are prerequisites for interpretable research.
Bottom Line
PPAP has one of the most intuitive and seductive mechanisms in the guide: it may amplify the motivation signal generated by what you are already doing. That is not the same as safe, selective, or smart motivation. With no human PK, dose-finding, efficacy trial, or long-term safety program, the mechanism remains a research hypothesis surrounded by vivid but unquantifiable anecdotes.
21.6 Dopamine-Transporter Inhibitors and Releasing Agents
21.6.1 Bupropion — A Slow-Building Antidepressant That Can Feel Fast at First
What it is: Bupropion is an aminoketone prescription antidepressant and smoking-cessation drug sold in immediate-release, sustained-release (SR), and extended-release (XL) forms. Its parent and active metabolites affect norepinephrine/dopamine transport and nicotinic acetylcholine receptors. It is treatment for an indicated disorder, not casual stimulation.
What it may feel like: The first days can feel very different from the eventual treatment. Some people get a “honeymoon” of wakefulness, libido, talkativeness, and cleaning the whole apartment; others get anxiety, anger, tinnitus, dry mouth, insomnia, or crushing fatigue. Over several weeks, responders describe the grayness lifting: ordinary accomplishments feel rewarding again and beginning life tasks stops feeling impossible. Nonresponders may remain awake without motivation, become emotionally flat, or experience worse memory and concentration.
The simplest description: Bupropion is not a single quick dopamine hit. It is a parent drug plus a convoy of long-lived active metabolites. The first activation can arrive quickly, while the antidepressant change is a slower adaptation measured in weeks.
How It Works
Bupropion and its metabolites inhibit norepinephrine and dopamine reuptake to different degrees and antagonize several nicotinic acetylcholine receptors. In humans, the noradrenergic contribution and active hydroxybupropion exposure are substantial; “dopamine antidepressant” is an oversimplification.
The drug reaches the CNS but is not centrally selective. Blood pressure, appetite, gastrointestinal function, sweating, seizure threshold, and hepatic drug interactions matter. CYP2B6 creates hydroxybupropion, while bupropion and metabolites strongly inhibit CYP2D6.
Dose and How It Is Taken
Current XL labels commonly begin at 150 mg once daily and may increase to 300 mg once daily for major depression, with product- and indication-specific limits. IR, SR, XL, and the 450/522-mg branded products are not interchangeable by schedule. These are prescription facts, not a healthy-user range; the author supplies no personal dose.
Bupropion hydrochloride is water-soluble, but modified-release tablets must be swallowed whole—never crushed, split, chewed, or dissolved unless that exact scored product’s label permits splitting. Destroying the release system can create a dangerous concentration spike and seizure risk. It may generally be taken with or without food; consistency and the exact product label matter more than fasting.
Timing and Pharmacokinetics
Evidence and Experiences
Evidence is strong for major depressive disorder, seasonal affective disorder, and smoking cessation. A depressed person regaining energy and interest is treatment of impairment, not proof that a healthy student becomes more intelligent. It is not an instant antidepressant and is not uniformly motivating.
Patient reports illustrate both time scales. Some describe an extremely energizing first week followed by a calmer durable reduction in fatigue; some only regain interest after three to six weeks; others get anxiety, fatigue, anhedonia, irritability, or impaired cognition. Energizing five-week account · Delayed return of pleasure · Energy without motivation · Fatigue/anxiety reports
Safety, Interactions, and Monitoring
Common adverse effects include dry mouth, nausea, constipation, insomnia, agitation, anxiety, tremor, sweating, headache, reduced appetite, and weight loss. The seizure risk is dose- and formulation-dependent. Stop and obtain urgent care for seizure, mania, psychosis, suicidal deterioration, severe hypertension, serious allergic reaction, confusion, or dangerous agitation.
Seizure disorder, current or prior bulimia/anorexia nervosa, and abrupt withdrawal from alcohol, benzodiazepines, barbiturates, or antiseizure drugs are major contraindication domains. MAO inhibitors—including clinically relevant linezolid or intravenous methylene blue situations—require strict separation. Other stimulants and seizure-threshold-lowering drugs increase risk. CYP2D6 inhibition can raise many antidepressants, antipsychotics, beta-blockers, antiarrhythmics, and other substrates.
Tolerance to the early “honeymoon” is common and does not mean the antidepressant stopped working. Physical dependence is not classically stimulant-like, but discontinuation can produce mood, sleep, irritability, or energy changes; prescriber-guided tapering is appropriate. There is no nootropic cycle.
Track blood pressure, pulse, sleep, appetite, weight, anxiety, irritability, tinnitus, libido, mood, suicidality, mania, seizure risk factors, and objective cognition. Use only a pharmacy-regulated formulation; release technology is part of the drug.
Bottom Line
Bupropion can be transformative when depression or nicotine dependence is the bottleneck. Its practical signature is often energy first, therapeutic meaning later. That same activation can become anxiety, insomnia, hypertension, cognitive worsening, or seizure risk, so it belongs in medical treatment—not a casual dopamine stack.
What it is: Bupropion is an aminoketone prescription antidepressant and smoking-cessation drug sold in immediate-release, sustained-release (SR), and extended-release (XL) forms. Its parent and active metabolites affect norepinephrine/dopamine transport and nicotinic acetylcholine receptors. It is treatment for an indicated disorder, not casual stimulation.
What it may feel like: The first days can feel very different from the eventual treatment. Some people get a “honeymoon” of wakefulness, libido, talkativeness, and cleaning the whole apartment; others get anxiety, anger, tinnitus, dry mouth, insomnia, or crushing fatigue. Over several weeks, responders describe the grayness lifting: ordinary accomplishments feel rewarding again and beginning life tasks stops feeling impossible. Nonresponders may remain awake without motivation, become emotionally flat, or experience worse memory and concentration.
The simplest description: Bupropion is not a single quick dopamine hit. It is a parent drug plus a convoy of long-lived active metabolites. The first activation can arrive quickly, while the antidepressant change is a slower adaptation measured in weeks.
How It Works
Bupropion and its metabolites inhibit norepinephrine and dopamine reuptake to different degrees and antagonize several nicotinic acetylcholine receptors. In humans, the noradrenergic contribution and active hydroxybupropion exposure are substantial; “dopamine antidepressant” is an oversimplification.
The drug reaches the CNS but is not centrally selective. Blood pressure, appetite, gastrointestinal function, sweating, seizure threshold, and hepatic drug interactions matter. CYP2B6 creates hydroxybupropion, while bupropion and metabolites strongly inhibit CYP2D6.
Dose and How It Is Taken
Current XL labels commonly begin at 150 mg once daily and may increase to 300 mg once daily for major depression, with product- and indication-specific limits. IR, SR, XL, and the 450/522-mg branded products are not interchangeable by schedule. These are prescription facts, not a healthy-user range; the author supplies no personal dose.
Bupropion hydrochloride is water-soluble, but modified-release tablets must be swallowed whole—never crushed, split, chewed, or dissolved unless that exact scored product’s label permits splitting. Destroying the release system can create a dangerous concentration spike and seizure risk. It may generally be taken with or without food; consistency and the exact product label matter more than fasting.
Timing and Pharmacokinetics
- Subjective onset: Activation or adverse effects can begin on Day 1–7; therapeutic mood benefit is slower.
- Pharmacologic onset: Parent and metabolite exposure begins after the first dose.
- Tmax: Roughly two hours for IR, three hours for SR, and five hours for XL; hydroxybupropion after XL peaks around seven hours.
- Absorption/bioavailability: Extensively absorbed, but absolute oral bioavailability is not firmly established because of first-pass metabolism and lack of a routine IV comparison.
- Full practical effect: Commonly two to six weeks, sometimes longer; the early energizing phase is not the final therapeutic response.
- Subjective duration: Modified-release products are designed for roughly all-day coverage.
- Half-life: Parent bupropion averages about 21 hours; active metabolite half-lives are commonly 20–37 hours.
- Accumulation/steady state: Parent and metabolites approach steady state in about eight days, with substantial metabolite accumulation.
- Near-complete elimination: Roughly five to eight days for most parent/active-metabolite exposure after stopping, although clinical changes and withdrawal-like symptoms may last longer.
- Metabolism/elimination: CYP2B6 and carbonyl-reduction pathways form hydroxy-, threo-, and erythrohydrobupropion; most recovered material leaves in urine as metabolites.
Evidence and Experiences
Evidence is strong for major depressive disorder, seasonal affective disorder, and smoking cessation. A depressed person regaining energy and interest is treatment of impairment, not proof that a healthy student becomes more intelligent. It is not an instant antidepressant and is not uniformly motivating.
Patient reports illustrate both time scales. Some describe an extremely energizing first week followed by a calmer durable reduction in fatigue; some only regain interest after three to six weeks; others get anxiety, fatigue, anhedonia, irritability, or impaired cognition. Energizing five-week account · Delayed return of pleasure · Energy without motivation · Fatigue/anxiety reports
Safety, Interactions, and Monitoring
Common adverse effects include dry mouth, nausea, constipation, insomnia, agitation, anxiety, tremor, sweating, headache, reduced appetite, and weight loss. The seizure risk is dose- and formulation-dependent. Stop and obtain urgent care for seizure, mania, psychosis, suicidal deterioration, severe hypertension, serious allergic reaction, confusion, or dangerous agitation.
Seizure disorder, current or prior bulimia/anorexia nervosa, and abrupt withdrawal from alcohol, benzodiazepines, barbiturates, or antiseizure drugs are major contraindication domains. MAO inhibitors—including clinically relevant linezolid or intravenous methylene blue situations—require strict separation. Other stimulants and seizure-threshold-lowering drugs increase risk. CYP2D6 inhibition can raise many antidepressants, antipsychotics, beta-blockers, antiarrhythmics, and other substrates.
Tolerance to the early “honeymoon” is common and does not mean the antidepressant stopped working. Physical dependence is not classically stimulant-like, but discontinuation can produce mood, sleep, irritability, or energy changes; prescriber-guided tapering is appropriate. There is no nootropic cycle.
Track blood pressure, pulse, sleep, appetite, weight, anxiety, irritability, tinnitus, libido, mood, suicidality, mania, seizure risk factors, and objective cognition. Use only a pharmacy-regulated formulation; release technology is part of the drug.
Bottom Line
Bupropion can be transformative when depression or nicotine dependence is the bottleneck. Its practical signature is often energy first, therapeutic meaning later. That same activation can become anxiety, insomnia, hypertension, cognitive worsening, or seizure risk, so it belongs in medical treatment—not a casual dopamine stack.
21.6.2 Oroxylin A — A Preclinical Flavone With Stimulant and GABA-Antagonist Possibilities
What it is: Oroxylin A is 5,7-dihydroxy-6-methoxyflavone, a flavonoid found in plants such as Scutellaria species and sold in some standardized extracts. Rodent studies suggest dopamine-transporter and GABA-A-receptor effects, but there is no controlled human nootropic program defining efficacy, dose, PK, or safety.
What it may feel like: The honest profile is unresolved. Sparse reports range from mild stimulation, alertness, and focus to anxiety, headache, dysphoria, insomnia, or feeling physically awful; many reports concern mixed botanical extracts or stimulant stacks. A clean “Sabroxy feeling” cannot automatically be assigned to pure Oroxylin A.
The simplest description: Oroxylin A may press the accelerator by prolonging dopamine signaling while partly loosening a GABA brake. That sounds pro-focus on paper, but removing inhibition can also create anxiety, tremor, insomnia, or seizure risk.
How It Works
Preclinical studies report DAT inhibition or dopamine-linked attention effects and negative modulation/antagonism at GABA-A receptors. The concentrations and exact targets producing each effect in humans are unknown. Antioxidant and neuroprotective findings in cells or rodents do not cancel acute CNS excitation.
Animal work demonstrates that Oroxylin A or related botanical exposures can reach the brain, but quantitative human BBB penetration and central-versus-peripheral balance are unknown. Extensive intestinal/hepatic glucuronidation and sulfation are expected to shape exposure.
Dose and How It Was Studied
There is no validated human nootropic or therapeutic dose, no approved product, and no author-supplied protocol. Amounts listed by extract vendors or experimenters are not clinical dose-finding evidence, particularly when the extract is only partly standardized.
Oroxylin A is poorly water-soluble and relatively lipophilic. Fat or an emulsified formulation might alter absorption, but no human study validates a “take with fat” enhancement rule. A botanical powder, standardized extract, pure free compound, and sodium-sulfonate derivative are different formulations and cannot share one PK profile.
Timing and Pharmacokinetics
Evidence and Experiences
Evidence for attention, memory, DAT effects, and GABA antagonism is mainly rodent or in vitro. It does not establish a healthy-human effect size, a safe therapeutic window, or superiority to characterized ADHD treatment. Botanical origin is not human clinical validation.
Pure-compound anecdotes are rare and stacks dominate. Some users describe useful stimulation; others describe anxiety, sweating, headache, insomnia, or feeling terrible, and commenters explicitly worry about GABA antagonism and seizures. Pure-compound discussion · Sparse Oroxylin A reports · Anecdotal update involving stacks
Safety, Interactions, and Monitoring
Human adverse-effect incidence is unknown. Plausible or reported problems include anxiety, agitation, tremor, insomnia, headache, sweating, palpitations, blood-pressure change, confusion, and seizure. Stop and seek urgent care for seizure, severe agitation, hallucinations, chest pain, fainting, major vital-sign change, or prolonged sleeplessness.
Avoid combining with stimulants, bupropion, MAO inhibitors, decongestants, other seizure-threshold-lowering drugs, or withdrawal from alcohol/benzodiazepines/GABAergic agents. Pregnancy, breastfeeding, minors, epilepsy, bipolar or psychotic illness, severe anxiety, and cardiovascular disease have no established safe-use basis.
Tolerance, dependence, withdrawal, cycling, and washout are unknown. Research-grade evaluation would require identity, assay, botanical-marker profile where relevant, impurities, residual solvents, and independent confirmation of the actual Oroxylin A fraction. Track pulse, blood pressure, sleep, anxiety, tremor, mood, and objective attention rather than subjective stimulation alone.
Bottom Line
Oroxylin A is interesting because its proposed mechanisms could plausibly sharpen attention. Those same mechanisms could plausibly remove too much inhibition. Until human PK, dose-response, and safety exist, it is a preclinical lead compound—not a practical natural alternative to prescription stimulants.
What it is: Oroxylin A is 5,7-dihydroxy-6-methoxyflavone, a flavonoid found in plants such as Scutellaria species and sold in some standardized extracts. Rodent studies suggest dopamine-transporter and GABA-A-receptor effects, but there is no controlled human nootropic program defining efficacy, dose, PK, or safety.
What it may feel like: The honest profile is unresolved. Sparse reports range from mild stimulation, alertness, and focus to anxiety, headache, dysphoria, insomnia, or feeling physically awful; many reports concern mixed botanical extracts or stimulant stacks. A clean “Sabroxy feeling” cannot automatically be assigned to pure Oroxylin A.
The simplest description: Oroxylin A may press the accelerator by prolonging dopamine signaling while partly loosening a GABA brake. That sounds pro-focus on paper, but removing inhibition can also create anxiety, tremor, insomnia, or seizure risk.
How It Works
Preclinical studies report DAT inhibition or dopamine-linked attention effects and negative modulation/antagonism at GABA-A receptors. The concentrations and exact targets producing each effect in humans are unknown. Antioxidant and neuroprotective findings in cells or rodents do not cancel acute CNS excitation.
Animal work demonstrates that Oroxylin A or related botanical exposures can reach the brain, but quantitative human BBB penetration and central-versus-peripheral balance are unknown. Extensive intestinal/hepatic glucuronidation and sulfation are expected to shape exposure.
Dose and How It Was Studied
There is no validated human nootropic or therapeutic dose, no approved product, and no author-supplied protocol. Amounts listed by extract vendors or experimenters are not clinical dose-finding evidence, particularly when the extract is only partly standardized.
Oroxylin A is poorly water-soluble and relatively lipophilic. Fat or an emulsified formulation might alter absorption, but no human study validates a “take with fat” enhancement rule. A botanical powder, standardized extract, pure free compound, and sodium-sulfonate derivative are different formulations and cannot share one PK profile.
Timing and Pharmacokinetics
- Subjective onset: Anecdotally 30–120 minutes, if noticeable.
- Pharmacologic onset: Unknown in humans.
- Tmax: Unknown for a validated human oral Oroxylin A product.
- Absorption/bioavailability: Human absolute bioavailability is unknown and likely limited by poor dissolution plus extensive phase-II metabolism.
- Full practical effect: Unknown.
- Subjective duration: Reports range from a few hours to no distinct effect.
- Half-life: Unknown in humans for the relevant formulations.
- Accumulation/steady state: Unknown; no repeat-dose human PK exists.
- Near-complete elimination: No defensible numerical washout can be calculated.
- Metabolism/elimination: Expected glucuronidation, sulfation, gut-microbial transformation, and biliary/urinary elimination; human contribution of active metabolites is unresolved.
Evidence and Experiences
Evidence for attention, memory, DAT effects, and GABA antagonism is mainly rodent or in vitro. It does not establish a healthy-human effect size, a safe therapeutic window, or superiority to characterized ADHD treatment. Botanical origin is not human clinical validation.
Pure-compound anecdotes are rare and stacks dominate. Some users describe useful stimulation; others describe anxiety, sweating, headache, insomnia, or feeling terrible, and commenters explicitly worry about GABA antagonism and seizures. Pure-compound discussion · Sparse Oroxylin A reports · Anecdotal update involving stacks
Safety, Interactions, and Monitoring
Human adverse-effect incidence is unknown. Plausible or reported problems include anxiety, agitation, tremor, insomnia, headache, sweating, palpitations, blood-pressure change, confusion, and seizure. Stop and seek urgent care for seizure, severe agitation, hallucinations, chest pain, fainting, major vital-sign change, or prolonged sleeplessness.
Avoid combining with stimulants, bupropion, MAO inhibitors, decongestants, other seizure-threshold-lowering drugs, or withdrawal from alcohol/benzodiazepines/GABAergic agents. Pregnancy, breastfeeding, minors, epilepsy, bipolar or psychotic illness, severe anxiety, and cardiovascular disease have no established safe-use basis.
Tolerance, dependence, withdrawal, cycling, and washout are unknown. Research-grade evaluation would require identity, assay, botanical-marker profile where relevant, impurities, residual solvents, and independent confirmation of the actual Oroxylin A fraction. Track pulse, blood pressure, sleep, anxiety, tremor, mood, and objective attention rather than subjective stimulation alone.
Bottom Line
Oroxylin A is interesting because its proposed mechanisms could plausibly sharpen attention. Those same mechanisms could plausibly remove too much inhibition. Until human PK, dose-response, and safety exist, it is a preclinical lead compound—not a practical natural alternative to prescription stimulants.
21.6.3 Methylphenidate — Making the Chosen Signal Easier to Hold
What it is: Methylphenidate is a Schedule II prescription stimulant used chiefly for ADHD and narcolepsy. Ordinary methylphenidate is a racemic piperidine compound containing d- and l-threo enantiomers; the d-enantiomer is the more active one, while dexmethylphenidate is that active enantiomer sold separately. Ritalin IR, Ritalin LA, Concerta, Jornay PM, liquid, chewable, and transdermal products are not merely different brand names: their delivery systems produce materially different timelines.
What it may feel like: In a responder with ADHD, it may feel less like being “sped up” and more like somebody turned down twenty televisions playing in the same room. One thought becomes easier to keep in front of you, an email can be answered without an hour of internal negotiation, background noise becomes less abrasive, and sitting still may stop feeling physically expensive. It does not supply judgment: without a written target, the same stronger grip can attach to reorganizing files, scrolling, or researching an irrelevant detail. Excessive exposure may feel like a tight forehead, internal buzzing, dread, robotic social behavior, irritability, emotional flattening, or being very awake but less mentally flexible.
The simplest description: Methylphenidate makes dopamine and norepinephrine signals harder to clear away. Imagine trying to read one sentence while somebody repeatedly erases it from the page: blocking DAT and NET leaves the useful sentence visible longer. That can improve selection and persistence when deficient ADHD circuitry is the bottleneck, but it can also turn focus into tunnel vision.
How It Works
Methylphenidate occupies the dopamine transporter (DAT) and norepinephrine transporter (NET), slowing reuptake and raising extracellular catecholamine signaling, especially in frontostriatal networks. Unlike amphetamine, it is not primarily a transporter substrate that enters the neuron and reverses transport or empties vesicles. It readily reaches the CNS, including the striatum and prefrontal systems, but it is not brain-exclusive: pulse, blood pressure, appetite, gastrointestinal function, sweating, and peripheral circulation remain involved.
The practical contrast with amphetamine is therefore signal preservation versus active release. That does not make methylphenidate weak, nor does a calm response prove a person has ADHD; response to a stimulant is not a diagnostic test.
Dose and How It Is Taken
Current immediate-release Ritalin labeling starts pediatric patients aged six and older at 5 mg twice daily and describes an adult average of 20–30 mg/day in divided doses, with a labeled maximum of 60 mg/day. Those numbers describe supervised treatment with one specific IR product—not a healthy-user range, not an equivalence table for Concerta or another extended product, and not permission to double a dose. The author supplies no personal dose.
Methylphenidate hydrochloride is a highly water-soluble salt, but that does not mean every product should be dissolved or taken fasted. The current IR label prefers dosing 30–45 minutes before meals, although its PK section reports no relevant food effect on total IR absorption. Modified-release tablets or beads must be swallowed or manipulated exactly as their own label permits: crushing Concerta or another controlled-release system can destroy the intended concentration curve. Alcohol can disrupt some modified-release products. A late dose can outlast the obvious focus and damage sleep.
Timing and Pharmacokinetics
Evidence and Experiences
Randomized clinical evidence is strong for reducing core ADHD symptoms, and formulations are also used in narcolepsy. That evidence concerns diagnosed impairment under titration and monitoring. In healthy, rested adults, any average cognitive improvement is smaller and less reliable; increased alertness or time-on-task can coexist with worse flexibility, calibration, sleep, or choice of task.
Recurring reports make the useful and misleading parts vivid. Responders describe the fog lifting, thoughts arriving one at a time, being able to wait without fidgeting, or simply finding themselves doing the next item on a list. Others feel only buzzing, fatigue, anxiety, disconnection, or no useful effect. A prominent first-dose calm or euphoria often fades, while functional benefit may remain; chasing the original feeling is not the same as treating symptoms. Reports also repeatedly warn that a mapped-out task list can produce smooth work, whereas no plan can produce four hours of highly organized irrelevance. Calm and reduced mental noise · Task initiation after IR methylphenidate · Focus, fixation, and crash descriptions · Nonresponse despite a noticeable “buzz”
Safety, Interactions, and Monitoring
Common adverse effects include reduced appetite, weight loss, nausea or abdominal pain, dry mouth, headache, sweating, anxiety, insomnia, tachycardia, and palpitations. The boxed warning covers abuse, misuse, addiction, overdose, and death. Serious risks include hypertension, arrhythmia in susceptible people, new psychosis or mania, worsening tics, seizures, peripheral vasculopathy/Raynaud-like symptoms, glaucoma or raised intraocular pressure, growth suppression in younger patients, and rare priapism.
Do not combine it with an MAO inhibitor or use it within the required 14-day separation; linezolid and intravenous methylene blue can matter in this context. Other stimulants, decongestants and sympathomimetics, some serotonergic or seizure-threshold-lowering drugs, antihypertensives, and certain anesthetics require clinical review. Cardiac disease, bipolar/psychotic vulnerability, glaucoma, tics, pregnancy, eating/weight concerns, and substance-use history materially change the calculation.
Stop and obtain urgent assessment for chest pain, unexplained fainting, severe hypertension, seizure, hallucinations, mania, dangerous agitation, a painful prolonged erection, blue/painful fingers or unexplained digital wounds, severe allergic reaction, or suicidal deterioration. Track resting pulse and blood pressure, sleep onset and duration, appetite, weight and growth where relevant, anxiety, mood, tics, circulation, refill behavior, and objective work accuracy—not merely hours spent staring at the task.
Tolerance to euphoria or the conspicuous first-day feeling can occur; therapeutic response does not necessarily vanish with it. Misuse, psychological reinforcement, physical dependence, and withdrawal fatigue, dysphoria, sleep change, or increased appetite are possible, especially after high or prolonged exposure. There is no evidence-based nootropic cycle, and medication breaks should be prescriber decisions rather than attempts to repeatedly restore a “kick.”
Use only a pharmacy-regulated product and verify the exact release form at every refill. Release engineering is part of the drug, counterfeit “Ritalin” can contain something else, and an IR milligram is not a timing-equivalent substitute for an ER milligram.
Bottom Line
For properly diagnosed ADHD, methylphenidate can convert “I know what I need to do but cannot hold the instruction in place” into ordinary, unremarkable task execution. It may feel calmer and less forceful than amphetamine, but it can still produce tunnel focus, appetite and sleep damage, cardiovascular strain, dependence, or a hard rebound. Its clinical value can be high; its healthy-user risk-benefit is poor without an indication and medical monitoring.
What it is: Methylphenidate is a Schedule II prescription stimulant used chiefly for ADHD and narcolepsy. Ordinary methylphenidate is a racemic piperidine compound containing d- and l-threo enantiomers; the d-enantiomer is the more active one, while dexmethylphenidate is that active enantiomer sold separately. Ritalin IR, Ritalin LA, Concerta, Jornay PM, liquid, chewable, and transdermal products are not merely different brand names: their delivery systems produce materially different timelines.
What it may feel like: In a responder with ADHD, it may feel less like being “sped up” and more like somebody turned down twenty televisions playing in the same room. One thought becomes easier to keep in front of you, an email can be answered without an hour of internal negotiation, background noise becomes less abrasive, and sitting still may stop feeling physically expensive. It does not supply judgment: without a written target, the same stronger grip can attach to reorganizing files, scrolling, or researching an irrelevant detail. Excessive exposure may feel like a tight forehead, internal buzzing, dread, robotic social behavior, irritability, emotional flattening, or being very awake but less mentally flexible.
The simplest description: Methylphenidate makes dopamine and norepinephrine signals harder to clear away. Imagine trying to read one sentence while somebody repeatedly erases it from the page: blocking DAT and NET leaves the useful sentence visible longer. That can improve selection and persistence when deficient ADHD circuitry is the bottleneck, but it can also turn focus into tunnel vision.
How It Works
Methylphenidate occupies the dopamine transporter (DAT) and norepinephrine transporter (NET), slowing reuptake and raising extracellular catecholamine signaling, especially in frontostriatal networks. Unlike amphetamine, it is not primarily a transporter substrate that enters the neuron and reverses transport or empties vesicles. It readily reaches the CNS, including the striatum and prefrontal systems, but it is not brain-exclusive: pulse, blood pressure, appetite, gastrointestinal function, sweating, and peripheral circulation remain involved.
The practical contrast with amphetamine is therefore signal preservation versus active release. That does not make methylphenidate weak, nor does a calm response prove a person has ADHD; response to a stimulant is not a diagnostic test.
Dose and How It Is Taken
Current immediate-release Ritalin labeling starts pediatric patients aged six and older at 5 mg twice daily and describes an adult average of 20–30 mg/day in divided doses, with a labeled maximum of 60 mg/day. Those numbers describe supervised treatment with one specific IR product—not a healthy-user range, not an equivalence table for Concerta or another extended product, and not permission to double a dose. The author supplies no personal dose.
Methylphenidate hydrochloride is a highly water-soluble salt, but that does not mean every product should be dissolved or taken fasted. The current IR label prefers dosing 30–45 minutes before meals, although its PK section reports no relevant food effect on total IR absorption. Modified-release tablets or beads must be swallowed or manipulated exactly as their own label permits: crushing Concerta or another controlled-release system can destroy the intended concentration curve. Alcohol can disrupt some modified-release products. A late dose can outlast the obvious focus and damage sleep.
Timing and Pharmacokinetics
- Subjective onset: Commonly about 20–60 minutes for IR; extended products vary and may have delayed or staged onset.
- Pharmacologic onset: Transporter occupancy begins as plasma concentration rises after the first dose.
- Tmax: Current Ritalin IR labeling reports about two hours; extended-release systems can create later or multiple peaks, so there is no universal “methylphenidate Tmax.”
- Absorption/bioavailability: Absorption is substantial, but first-pass CES1 metabolism makes absolute bioavailability stereoselective and variable: about 22 ± 8% for d-methylphenidate and 5 ± 3% for the l-enantiomer in the current IR label.
- Full practical effect: Symptom change can be evident on the first effective dose, while finding a dose and release curve that remains useful without appetite, mood, cardiovascular, or sleep costs can take weeks of titration.
- Subjective duration: Roughly three to four hours for IR; common long-acting products range from approximately six to twelve hours, but the exact product—not the ingredient name—determines the window.
- Half-life: The intrinsic plasma half-life is generally about two to three hours and is not the same as a controlled-release product’s duration.
- Accumulation/steady state: Little parent-drug accumulation is expected with ordinary once-daily or divided clinical use because the half-life is short. Day-to-day effects can still change through sleep loss, appetite suppression, adaptation, and release-form timing.
- Near-complete elimination: Most active parent exposure from an IR dose is negligible after roughly 12–18 hours in a typical metabolizer; the label reports that 78–97% of the dose leaves in urine as metabolites within 48–96 hours. Extended delivery shifts when the last portion enters the body.
- Metabolism/elimination: CES1 de-esterifies methylphenidate mainly to minimally active ritalinic acid; metabolites are excreted predominantly in urine. CES1 variation, ethanol, formulation, age, and body size can change exposure.
Evidence and Experiences
Randomized clinical evidence is strong for reducing core ADHD symptoms, and formulations are also used in narcolepsy. That evidence concerns diagnosed impairment under titration and monitoring. In healthy, rested adults, any average cognitive improvement is smaller and less reliable; increased alertness or time-on-task can coexist with worse flexibility, calibration, sleep, or choice of task.
Recurring reports make the useful and misleading parts vivid. Responders describe the fog lifting, thoughts arriving one at a time, being able to wait without fidgeting, or simply finding themselves doing the next item on a list. Others feel only buzzing, fatigue, anxiety, disconnection, or no useful effect. A prominent first-dose calm or euphoria often fades, while functional benefit may remain; chasing the original feeling is not the same as treating symptoms. Reports also repeatedly warn that a mapped-out task list can produce smooth work, whereas no plan can produce four hours of highly organized irrelevance. Calm and reduced mental noise · Task initiation after IR methylphenidate · Focus, fixation, and crash descriptions · Nonresponse despite a noticeable “buzz”
Safety, Interactions, and Monitoring
Common adverse effects include reduced appetite, weight loss, nausea or abdominal pain, dry mouth, headache, sweating, anxiety, insomnia, tachycardia, and palpitations. The boxed warning covers abuse, misuse, addiction, overdose, and death. Serious risks include hypertension, arrhythmia in susceptible people, new psychosis or mania, worsening tics, seizures, peripheral vasculopathy/Raynaud-like symptoms, glaucoma or raised intraocular pressure, growth suppression in younger patients, and rare priapism.
Do not combine it with an MAO inhibitor or use it within the required 14-day separation; linezolid and intravenous methylene blue can matter in this context. Other stimulants, decongestants and sympathomimetics, some serotonergic or seizure-threshold-lowering drugs, antihypertensives, and certain anesthetics require clinical review. Cardiac disease, bipolar/psychotic vulnerability, glaucoma, tics, pregnancy, eating/weight concerns, and substance-use history materially change the calculation.
Stop and obtain urgent assessment for chest pain, unexplained fainting, severe hypertension, seizure, hallucinations, mania, dangerous agitation, a painful prolonged erection, blue/painful fingers or unexplained digital wounds, severe allergic reaction, or suicidal deterioration. Track resting pulse and blood pressure, sleep onset and duration, appetite, weight and growth where relevant, anxiety, mood, tics, circulation, refill behavior, and objective work accuracy—not merely hours spent staring at the task.
Tolerance to euphoria or the conspicuous first-day feeling can occur; therapeutic response does not necessarily vanish with it. Misuse, psychological reinforcement, physical dependence, and withdrawal fatigue, dysphoria, sleep change, or increased appetite are possible, especially after high or prolonged exposure. There is no evidence-based nootropic cycle, and medication breaks should be prescriber decisions rather than attempts to repeatedly restore a “kick.”
Use only a pharmacy-regulated product and verify the exact release form at every refill. Release engineering is part of the drug, counterfeit “Ritalin” can contain something else, and an IR milligram is not a timing-equivalent substitute for an ER milligram.
Bottom Line
For properly diagnosed ADHD, methylphenidate can convert “I know what I need to do but cannot hold the instruction in place” into ordinary, unremarkable task execution. It may feel calmer and less forceful than amphetamine, but it can still produce tunnel focus, appetite and sleep damage, cardiovascular strain, dependence, or a hard rebound. Its clinical value can be high; its healthy-user risk-benefit is poor without an indication and medical monitoring.
21.6.4 Mixed Amphetamine Salts / Adderall — More Drive, but No Steering Wheel
What it is: Adderall is a Schedule II prescription mixture of dextroamphetamine and levoamphetamine salts in a 3:1 ratio. Immediate-release tablets and Adderall XR capsules deliver the same two isomers on different timelines. Dextroamphetamine contributes more of the central cognitive/behavioral effect, while levoamphetamine adds relatively more noradrenergic and peripheral physical texture.
What it may feel like: In a well-matched ADHD patient, clutter can become a sequence: open the document, write the paragraph, send the email. Boring work may acquire urgency, fatigue recedes, conversation becomes more directed, and continuing a task requires less willpower. Compared with methylphenidate, the effect is often described as more propulsive—not only easier focus, but a stronger sense that something matters and should be done now. That propulsion has no steering wheel. If the first activity is gaming, arguing, cleaning one corner, or researching an irrelevant question, the person may become extraordinarily committed to the wrong thing. Too much can feel euphoric, invincible, jaw-tight, socially overconfident, anxious, compulsive, irritable, or unable to stop even after accuracy deteriorates.
The simplest description: Methylphenidate mainly keeps existing catecholamine messages from being cleared; amphetamine also enters the signaling terminal and pushes more dopamine and norepinephrine outward. It is closer to increasing both the volume and persistence of a broadcast. The result can be genuine symptom control, but “I worked for ten hours” does not prove the ten hours were intelligent, accurate, or worth the sleep debt.
How It Works
Amphetamine crosses the blood-brain barrier and enters catecholamine neurons through DAT and NET. Through transporter, vesicular (VMAT2), and intracellular signaling including TAAR1, it increases cytosolic dopamine/norepinephrine and promotes reverse transport while also reducing reuptake. Central effects improve ADHD symptoms in responders; peripheral sympathetic action raises pulse and blood pressure, suppresses appetite, constricts vessels, and can make the body feel activated even when the mind feels calm.
The levo isomer is not inert. Its relatively stronger noradrenergic/peripheral contribution is one reason mixed salts can feel more physical than pure dextroamphetamine, although individual response and formulation often matter more than a neat subjective rule.
Dose and How It Is Taken
Current IR labeling starts children aged six and older at 5 mg once or twice daily, increasing only under supervision; current Adderall XR labeling recommends 20 mg once each morning for adults with ADHD, with age- and renal-function-specific regimens. Those are labeled treatment facts, not a healthy-student dose range, and IR and XR milligrams do not produce the same curve. The author supplies no personal dose.
The pharmaceutical salts are water-soluble, but they should be used only in the prescribed formulation. IR tablets are swallowed as labeled. XR capsules are swallowed whole or may be opened and the entire bead contents sprinkled on applesauce under the current label; beads must not be chewed, crushed, divided, or stored for later. A high-fat meal does not reduce total XR exposure but can delay the peak by roughly 2.5 hours. Morning administration matters because a person can feel “finished” while enough amphetamine remains to fragment sleep.
Timing and Pharmacokinetics
Evidence and Experiences
Randomized evidence is strong for ADHD, and IR mixed salts are also labeled for narcolepsy. In the current adult XR trial, 20, 40, and 60 mg groups improved relative to placebo, but there was not adequate evidence that doses above 20 mg/day added benefit. Treatment of a diagnosed deficit is not evidence that a healthy, rested student acquires better judgment or fluid intelligence; stimulant studies in healthy users show state- and task-dependent gains, and confidence may rise more consistently than accuracy.
Recurring reports split into three recognizable patterns. Responders say the brain becomes quiet and tasks stop “repelling” them; some feel calm enough to nap. Others get energy but still choose distractions—proof that activation is not motivation and focus is not priority. A third group describes appetite disappearing, hours passing without breaks, followed by headache, fatigue, irritability, sadness, or a short temper when the contrastive rebound arrives. Poor hydration, missed food, excessive caffeine/nicotine, and borrowed sleep can amplify what gets called a “crash,” but that does not make the crash imaginary. Does Adderall pull a person toward work? Mixed answers · Productivity followed by shorter functional hours · Quiet-brain reports across stimulant users · Mental burnout despite better function
Safety, Interactions, and Monitoring
Common adverse effects include appetite suppression, weight loss, dry mouth, insomnia, headache, abdominal symptoms, anxiety, irritability, sweating, jaw tension, increased heart rate, and higher blood pressure. It carries a boxed warning for abuse, misuse, addiction, overdose, and death. Serious hazards include arrhythmia or cardiac events in susceptible people, severe hypertension, psychosis or mania, seizure, serotonin syndrome, tics, peripheral vasculopathy/Raynaud-like injury, prolonged erections, and dangerous agitation or hyperthermia.
MAO inhibitors are contraindicated during use and for the required 14-day separation; this includes important linezolid and intravenous methylene-blue scenarios. Serotonergic drugs, CYP2D6 inhibitors, other stimulants, decongestants, sympathomimetics, and seizure-threshold-lowering drugs require review. Acidifying agents such as large ascorbic-acid exposures can lower amphetamine blood levels, while alkalinizing agents such as sodium bicarbonate can raise and prolong them; this is an interaction to avoid improvising around, not a “biohack.” Serious cardiac disease, hypertension, bipolar/psychotic risk, hyperthyroidism, glaucoma, pregnancy, renal impairment, tics, eating problems, and substance-use history change the risk materially.
Stop and seek urgent care for exertional chest pain, fainting, severe headache with marked hypertension, seizure, hallucinations, mania, severe agitation, hyperthermia, rigid/clonic movements or other serotonin-syndrome signs, blue/painful fingers or wounds, severe allergic reaction, or suicidal collapse. Track pulse, blood pressure, sleep, weight/appetite, mood, anxiety, tics, circulation, dose timing, compulsive behavior, refill escalation, and actual accuracy/output. Put food, water, breaks, and the intended task in place before onset; the drug may suppress the signals that would otherwise remind somebody to do so.
Tolerance to euphoria, appetite suppression, or obvious activation can develop. Psychological reinforcement, physical dependence, escalating use, and withdrawal fatigue, hypersomnia, increased appetite, depression, or dysphoria are established risks. There is no evidence-based nootropic cycle that neutralizes addiction or cardiovascular risk; prescribed medication holidays are individualized clinical decisions.
Use only a pharmacy-dispensed product stored securely. Counterfeit tablets sold as “Adderall” may contain methamphetamine, fentanyl, or another drug, and visual similarity proves nothing. The release system and exact salt formulation are part of product identity.
Bottom Line
Adderall can be enormously valuable when ADHD prevents a person from converting intention into action. Its signature is more drive plus more persistence, but it cannot tell the user what deserves that drive. Outside a diagnosed indication, the apparent productivity can be purchased with misdirected hyperfocus, sleep and appetite loss, cardiovascular strain, tolerance, dependence, and confidence that outruns accuracy.
What it is: Adderall is a Schedule II prescription mixture of dextroamphetamine and levoamphetamine salts in a 3:1 ratio. Immediate-release tablets and Adderall XR capsules deliver the same two isomers on different timelines. Dextroamphetamine contributes more of the central cognitive/behavioral effect, while levoamphetamine adds relatively more noradrenergic and peripheral physical texture.
What it may feel like: In a well-matched ADHD patient, clutter can become a sequence: open the document, write the paragraph, send the email. Boring work may acquire urgency, fatigue recedes, conversation becomes more directed, and continuing a task requires less willpower. Compared with methylphenidate, the effect is often described as more propulsive—not only easier focus, but a stronger sense that something matters and should be done now. That propulsion has no steering wheel. If the first activity is gaming, arguing, cleaning one corner, or researching an irrelevant question, the person may become extraordinarily committed to the wrong thing. Too much can feel euphoric, invincible, jaw-tight, socially overconfident, anxious, compulsive, irritable, or unable to stop even after accuracy deteriorates.
The simplest description: Methylphenidate mainly keeps existing catecholamine messages from being cleared; amphetamine also enters the signaling terminal and pushes more dopamine and norepinephrine outward. It is closer to increasing both the volume and persistence of a broadcast. The result can be genuine symptom control, but “I worked for ten hours” does not prove the ten hours were intelligent, accurate, or worth the sleep debt.
How It Works
Amphetamine crosses the blood-brain barrier and enters catecholamine neurons through DAT and NET. Through transporter, vesicular (VMAT2), and intracellular signaling including TAAR1, it increases cytosolic dopamine/norepinephrine and promotes reverse transport while also reducing reuptake. Central effects improve ADHD symptoms in responders; peripheral sympathetic action raises pulse and blood pressure, suppresses appetite, constricts vessels, and can make the body feel activated even when the mind feels calm.
The levo isomer is not inert. Its relatively stronger noradrenergic/peripheral contribution is one reason mixed salts can feel more physical than pure dextroamphetamine, although individual response and formulation often matter more than a neat subjective rule.
Dose and How It Is Taken
Current IR labeling starts children aged six and older at 5 mg once or twice daily, increasing only under supervision; current Adderall XR labeling recommends 20 mg once each morning for adults with ADHD, with age- and renal-function-specific regimens. Those are labeled treatment facts, not a healthy-student dose range, and IR and XR milligrams do not produce the same curve. The author supplies no personal dose.
The pharmaceutical salts are water-soluble, but they should be used only in the prescribed formulation. IR tablets are swallowed as labeled. XR capsules are swallowed whole or may be opened and the entire bead contents sprinkled on applesauce under the current label; beads must not be chewed, crushed, divided, or stored for later. A high-fat meal does not reduce total XR exposure but can delay the peak by roughly 2.5 hours. Morning administration matters because a person can feel “finished” while enough amphetamine remains to fragment sleep.
Timing and Pharmacokinetics
- Subjective onset: Often about 20–60 minutes for IR and roughly 45–120 minutes for XR, with wide variation from food, formulation, expectations, and baseline state.
- Pharmacologic onset: Catecholamine transporter and release effects begin after absorption on the first dose.
- Tmax: About three hours for IR and seven hours for Adderall XR; a high-fat meal can push the XR peak later.
- Absorption/bioavailability: Oral amphetamine is well absorbed and shows approximately dose-proportional exposure across labeled ranges. Exact exposure depends on GI conditions, product, renal function, and urinary pH; “water-soluble” does not make dissolved or altered-route use safe.
- Full practical effect: ADHD symptom change can occur on the first dose, but establishing whether the benefit survives appetite, sleep, mood, cardiovascular, and rebound costs requires gradual titration and repeated-day observation.
- Subjective duration: Commonly about four to six hours for IR and eight to twelve hours for XR, but residual activation and insomnia can outlast felt productivity.
- Half-life: In adults, approximately 10 hours for d-amphetamine and 13 hours for l-amphetamine; current IR labeling gives broader means of about 9.8–11 and 11.5–13.8 hours, respectively.
- Accumulation/steady state: With once-daily use, repeated exposure approaches its ordinary pattern over roughly two to three days; current XR labeling reports no unexpected accumulation. Sleep and appetite deficits can accumulate even when plasma PK is predictable.
- Near-complete elimination: Approximately two to three days after a final ordinary dose for most parent exposure, but acidic urine can shorten and alkaline urine can markedly prolong elimination; renal/hepatic impairment can extend it further.
- Metabolism/elimination: CYP2D6 contributes to 4-hydroxyamphetamine formation, with additional oxidative and deamination pathways. A substantial and highly variable fraction leaves unchanged in urine; urinary recovery ranges dramatically with pH and flow.
Evidence and Experiences
Randomized evidence is strong for ADHD, and IR mixed salts are also labeled for narcolepsy. In the current adult XR trial, 20, 40, and 60 mg groups improved relative to placebo, but there was not adequate evidence that doses above 20 mg/day added benefit. Treatment of a diagnosed deficit is not evidence that a healthy, rested student acquires better judgment or fluid intelligence; stimulant studies in healthy users show state- and task-dependent gains, and confidence may rise more consistently than accuracy.
Recurring reports split into three recognizable patterns. Responders say the brain becomes quiet and tasks stop “repelling” them; some feel calm enough to nap. Others get energy but still choose distractions—proof that activation is not motivation and focus is not priority. A third group describes appetite disappearing, hours passing without breaks, followed by headache, fatigue, irritability, sadness, or a short temper when the contrastive rebound arrives. Poor hydration, missed food, excessive caffeine/nicotine, and borrowed sleep can amplify what gets called a “crash,” but that does not make the crash imaginary. Does Adderall pull a person toward work? Mixed answers · Productivity followed by shorter functional hours · Quiet-brain reports across stimulant users · Mental burnout despite better function
Safety, Interactions, and Monitoring
Common adverse effects include appetite suppression, weight loss, dry mouth, insomnia, headache, abdominal symptoms, anxiety, irritability, sweating, jaw tension, increased heart rate, and higher blood pressure. It carries a boxed warning for abuse, misuse, addiction, overdose, and death. Serious hazards include arrhythmia or cardiac events in susceptible people, severe hypertension, psychosis or mania, seizure, serotonin syndrome, tics, peripheral vasculopathy/Raynaud-like injury, prolonged erections, and dangerous agitation or hyperthermia.
MAO inhibitors are contraindicated during use and for the required 14-day separation; this includes important linezolid and intravenous methylene-blue scenarios. Serotonergic drugs, CYP2D6 inhibitors, other stimulants, decongestants, sympathomimetics, and seizure-threshold-lowering drugs require review. Acidifying agents such as large ascorbic-acid exposures can lower amphetamine blood levels, while alkalinizing agents such as sodium bicarbonate can raise and prolong them; this is an interaction to avoid improvising around, not a “biohack.” Serious cardiac disease, hypertension, bipolar/psychotic risk, hyperthyroidism, glaucoma, pregnancy, renal impairment, tics, eating problems, and substance-use history change the risk materially.
Stop and seek urgent care for exertional chest pain, fainting, severe headache with marked hypertension, seizure, hallucinations, mania, severe agitation, hyperthermia, rigid/clonic movements or other serotonin-syndrome signs, blue/painful fingers or wounds, severe allergic reaction, or suicidal collapse. Track pulse, blood pressure, sleep, weight/appetite, mood, anxiety, tics, circulation, dose timing, compulsive behavior, refill escalation, and actual accuracy/output. Put food, water, breaks, and the intended task in place before onset; the drug may suppress the signals that would otherwise remind somebody to do so.
Tolerance to euphoria, appetite suppression, or obvious activation can develop. Psychological reinforcement, physical dependence, escalating use, and withdrawal fatigue, hypersomnia, increased appetite, depression, or dysphoria are established risks. There is no evidence-based nootropic cycle that neutralizes addiction or cardiovascular risk; prescribed medication holidays are individualized clinical decisions.
Use only a pharmacy-dispensed product stored securely. Counterfeit tablets sold as “Adderall” may contain methamphetamine, fentanyl, or another drug, and visual similarity proves nothing. The release system and exact salt formulation are part of product identity.
Bottom Line
Adderall can be enormously valuable when ADHD prevents a person from converting intention into action. Its signature is more drive plus more persistence, but it cannot tell the user what deserves that drive. Outside a diagnosed indication, the apparent productivity can be purchased with misdirected hyperfocus, sleep and appetite loss, cardiovascular strain, tolerance, dependence, and confidence that outruns accuracy.
21.6.5 Lisdexamfetamine / Vyvanse — A Slow Conversion Into Dextroamphetamine
What it is: Lisdexamfetamine is a Schedule II prodrug in which dextroamphetamine is covalently linked to L-lysine, commonly supplied as the dimesylate salt in Vyvanse capsules or chewable tablets. The parent compound is not the active monoamine-transporter drug; red blood cells hydrolyze it into dextroamphetamine and lysine after absorption. It is approved for ADHD and for moderate-to-severe binge-eating disorder in adults, not for weight loss.
What it may feel like: Many responders do not feel a sharp “kick.” Ninety minutes into the morning, they may simply notice that they have answered messages, remained in one document, and stopped bargaining with every minor task. Compared with IR amphetamine, the rise and fall often feel smoother, with fewer obvious peaks. That same long curve can feel unforgiving when the match is poor: appetite can disappear for most of the day, social warmth can flatten, the jaw or body can stay tense, and evening may bring irritability, sadness, hunger, headache, or leaden fatigue. Some people feel nothing useful; others feel intensely anxious or discover that smooth hyperfocus is still hyperfocus on the wrong task.
The simplest description: Vyvanse is a sealed packet that the blood opens gradually. Swallowing it does not deliver active dextroamphetamine all at once; red-cell conversion controls the ramp. That makes the experience less abrupt than many immediate-release products, but it does not turn amphetamine into a mild supplement or remove its dependence and cardiovascular risks.
How It Works
After intestinal absorption, red-blood-cell hydrolysis releases dextroamphetamine. The active drug crosses the blood-brain barrier, enters catecholamine neurons through DAT and NET, and increases dopamine and norepinephrine release through transporter, vesicular, and intracellular mechanisms while reducing reuptake. The parent lisdexamfetamine does not itself bind DAT or NET in vitro.
Conversion is largely outside CYP enzymes, which helps produce relatively consistent exposure, but the resulting dextroamphetamine is centrally and peripherally active. Pulse, blood pressure, appetite, temperature regulation, sleep, and circulation remain part of the pharmacology. A smoother concentration curve can lower the temptation to chase peaks for some patients; it does not eliminate abuse potential, and oral misuse can still be reinforcing.
Dose and How It Is Taken
The current label starts ADHD treatment in patients aged six and older and adult binge-eating treatment at 30 mg once in the morning, titrating by indication and response to a maximum of 70 mg/day; renal impairment lowers permitted maxima. These are prescription-treatment parameters—not a healthy-user range—and a 30 mg lisdexamfetamine capsule is not 30 mg of dextroamphetamine. The author supplies no personal dose.
Lisdexamfetamine dimesylate is water-soluble. The label permits a capsule to be swallowed whole or its entire contents mixed with water, orange juice, or yogurt and consumed immediately; chewable tablets must be chewed thoroughly. A single capsule/tablet must not be divided into multiple doses. Dissolving it does not bypass red-cell conversion or make it immediate-release. It is taken in the morning with or without food; a high-fat meal or yogurt delays the dextroamphetamine peak by about one hour without materially changing total capsule exposure. Afternoon use can produce insomnia.
Timing and Pharmacokinetics
Evidence and Experiences
Human randomized evidence is strong for ADHD and adult moderate-to-severe binge-eating disorder. It does not establish a safe productivity drug for a healthy, rested person, and the label explicitly says Vyvanse is not a weight-loss treatment. In clinical studies, improvement can span a school or work day; the magnitude, useful duration, and tolerability remain individual.
Recurring reports often describe a quiet, gradual moment in which “my brain works” rather than a rush. Some experience reliable all-day planning, fewer food obsessions, or less fidgeting. Others report early wear-off, no response, feeling emotionally unavailable, or a dramatic evening crash of fatigue, low mood, irritability, rebound hunger, headache, and anxiety. Users repeatedly observe that suppressed hunger and thirst can conceal missed food or dehydration until the drug fades; this is a plausible amplifier, not proof that every rebound is nutritional. Smooth benefit followed by an early severe crash · Crash, hidden fatigue, and dehydration reports · Focus and reduced food obsession with evening irritability · First-day benefit, appetite loss, and leaden fatigue
Safety, Interactions, and Monitoring
Common adverse effects in ADHD trials include decreased appetite and weight, insomnia, dry mouth, anxiety, irritability, nausea, abdominal symptoms, dizziness, and vomiting. Binge-eating trials also commonly reported constipation, jitteriness, and increased heart rate. The boxed warning covers abuse, misuse, addiction, overdose, and death. Serious risks include cardiac events in susceptible patients, hypertension, psychosis or mania, serotonin syndrome, seizure, tics, peripheral vasculopathy/Raynaud-like injury, rhabdomyolysis, intestinal ischemia, and prolonged erections.
MAO inhibitors are contraindicated during treatment and within the required 14-day separation, including relevant linezolid or intravenous methylene-blue situations. Serotonergic agents, CYP2D6 inhibitors, other stimulants/sympathomimetics, and seizure-threshold-lowering drugs require review. Acidifying agents can lower amphetamine exposure and alkalinizing agents can raise it; do not manipulate urinary pH to alter the effect. Serious cardiac disease, bipolar or psychotic vulnerability, pregnancy, breastfeeding, tics, substance-use risk, and renal impairment need specific medical consideration.
Stop and obtain urgent assessment for chest pain, unexplained fainting, severe hypertension, seizure, hallucinations, mania, dangerous agitation, hyperthermia or clonus, blue/painful fingers or wounds, severe allergic reaction, severe abdominal pain/bloody stool, or suicidal deterioration. Track pulse, blood pressure, sleep, appetite, weight/growth where relevant, hydration, mood, anxiety, tics, circulation, compulsive behavior, actual work accuracy, and whether the useful window is followed by a disabled evening.
Tolerance to obvious stimulation or euphoria can develop; a less noticeable dose may still be clinically effective. Amphetamine-class misuse, psychological reinforcement, physical dependence, and withdrawal fatigue, hypersomnia, depression, dysphoria, and increased appetite remain possible. The prodrug curve is not an anti-addiction shield, and no enhancement “cycle” makes unsupervised use safe. Prescriber-directed breaks or washouts are clinical decisions.
Use a pharmacy-regulated capsule or chewable tablet, verify the manufacturer and strength, and store it securely. Counterfeit “Vyvanse” has no reliable prodrug identity, and subjective differences between fills cannot establish a quality defect without objective testing.
Bottom Line
Vyvanse can provide a long, quiet bridge from intention to execution when ADHD or binge-eating disorder is the actual impairment. Its defining feature is gradual conversion into dextroamphetamine, which often feels smoother than IR amphetamine but can still suppress food, flatten emotion, prolong insomnia, create rebound, and produce dependence or cardiovascular harm. Smooth does not mean weak, safe for casual enhancement, or capable of choosing the right task.
What it is: Lisdexamfetamine is a Schedule II prodrug in which dextroamphetamine is covalently linked to L-lysine, commonly supplied as the dimesylate salt in Vyvanse capsules or chewable tablets. The parent compound is not the active monoamine-transporter drug; red blood cells hydrolyze it into dextroamphetamine and lysine after absorption. It is approved for ADHD and for moderate-to-severe binge-eating disorder in adults, not for weight loss.
What it may feel like: Many responders do not feel a sharp “kick.” Ninety minutes into the morning, they may simply notice that they have answered messages, remained in one document, and stopped bargaining with every minor task. Compared with IR amphetamine, the rise and fall often feel smoother, with fewer obvious peaks. That same long curve can feel unforgiving when the match is poor: appetite can disappear for most of the day, social warmth can flatten, the jaw or body can stay tense, and evening may bring irritability, sadness, hunger, headache, or leaden fatigue. Some people feel nothing useful; others feel intensely anxious or discover that smooth hyperfocus is still hyperfocus on the wrong task.
The simplest description: Vyvanse is a sealed packet that the blood opens gradually. Swallowing it does not deliver active dextroamphetamine all at once; red-cell conversion controls the ramp. That makes the experience less abrupt than many immediate-release products, but it does not turn amphetamine into a mild supplement or remove its dependence and cardiovascular risks.
How It Works
After intestinal absorption, red-blood-cell hydrolysis releases dextroamphetamine. The active drug crosses the blood-brain barrier, enters catecholamine neurons through DAT and NET, and increases dopamine and norepinephrine release through transporter, vesicular, and intracellular mechanisms while reducing reuptake. The parent lisdexamfetamine does not itself bind DAT or NET in vitro.
Conversion is largely outside CYP enzymes, which helps produce relatively consistent exposure, but the resulting dextroamphetamine is centrally and peripherally active. Pulse, blood pressure, appetite, temperature regulation, sleep, and circulation remain part of the pharmacology. A smoother concentration curve can lower the temptation to chase peaks for some patients; it does not eliminate abuse potential, and oral misuse can still be reinforcing.
Dose and How It Is Taken
The current label starts ADHD treatment in patients aged six and older and adult binge-eating treatment at 30 mg once in the morning, titrating by indication and response to a maximum of 70 mg/day; renal impairment lowers permitted maxima. These are prescription-treatment parameters—not a healthy-user range—and a 30 mg lisdexamfetamine capsule is not 30 mg of dextroamphetamine. The author supplies no personal dose.
Lisdexamfetamine dimesylate is water-soluble. The label permits a capsule to be swallowed whole or its entire contents mixed with water, orange juice, or yogurt and consumed immediately; chewable tablets must be chewed thoroughly. A single capsule/tablet must not be divided into multiple doses. Dissolving it does not bypass red-cell conversion or make it immediate-release. It is taken in the morning with or without food; a high-fat meal or yogurt delays the dextroamphetamine peak by about one hour without materially changing total capsule exposure. Afternoon use can produce insomnia.
Timing and Pharmacokinetics
- Subjective onset: Commonly about one to two hours, sometimes subtler than IR amphetamine; controlled pediatric data found significant behavioral separation from placebo beginning around two hours in one study.
- Pharmacologic onset: Parent absorption and red-cell conversion begin after the first oral dose.
- Tmax: Parent lisdexamfetamine reaches Tmax at about one hour. Dextroamphetamine peaks at about 3.5 hours after capsules under studied fasted conditions and about 4.4 hours after chewable tablets; food can delay the active peak by roughly one hour.
- Absorption/bioavailability: Oral exposure is reliable, and solution versus intact capsule produced equivalent dextroamphetamine AUC after fasting. A consumer-friendly absolute bioavailability percentage is not established in the current label; product and renal function still matter.
- Full practical effect: Useful ADHD effects can appear on the first dose, but determining a stable treatment response takes gradual titration and observation of the whole day—including appetite, mood, sleep, and rebound—not merely the best morning hours.
- Subjective duration: Commonly ten to fourteen hours, although some report only five to eight useful hours and others remain sleep-disrupted after perceived focus ends. Controlled studies detected benefit through 12–13 hours in pediatric classroom settings.
- Half-life: Unconverted lisdexamfetamine averages less than one hour and is generally unquantifiable by eight hours. Active dextroamphetamine averages about 10–11.3 hours in healthy adults.
- Accumulation/steady state: The active drug’s repeated-day pattern is reached over roughly two to three days; the current label reports no accumulation of lisdexamfetamine or dextroamphetamine at steady state in studied healthy adults. Functional costs such as missed food and sleep can nevertheless accumulate.
- Near-complete elimination: Parent lisdexamfetamine disappears the same day; most active dextroamphetamine exposure is gone after roughly two to three days, with urinary pH and renal function capable of shortening or extending that window. Radioactivity recovery was about 96% in urine over 120 hours.
- Metabolism/elimination: Red blood cells cleave lisdexamfetamine without CYP metabolism. Released dextroamphetamine undergoes amphetamine metabolic pathways and pH-dependent renal excretion; about 42% of a radiolabeled dose was recovered in urine as amphetamine, 25% as hippuric acid, and 2% as intact lisdexamfetamine.
Evidence and Experiences
Human randomized evidence is strong for ADHD and adult moderate-to-severe binge-eating disorder. It does not establish a safe productivity drug for a healthy, rested person, and the label explicitly says Vyvanse is not a weight-loss treatment. In clinical studies, improvement can span a school or work day; the magnitude, useful duration, and tolerability remain individual.
Recurring reports often describe a quiet, gradual moment in which “my brain works” rather than a rush. Some experience reliable all-day planning, fewer food obsessions, or less fidgeting. Others report early wear-off, no response, feeling emotionally unavailable, or a dramatic evening crash of fatigue, low mood, irritability, rebound hunger, headache, and anxiety. Users repeatedly observe that suppressed hunger and thirst can conceal missed food or dehydration until the drug fades; this is a plausible amplifier, not proof that every rebound is nutritional. Smooth benefit followed by an early severe crash · Crash, hidden fatigue, and dehydration reports · Focus and reduced food obsession with evening irritability · First-day benefit, appetite loss, and leaden fatigue
Safety, Interactions, and Monitoring
Common adverse effects in ADHD trials include decreased appetite and weight, insomnia, dry mouth, anxiety, irritability, nausea, abdominal symptoms, dizziness, and vomiting. Binge-eating trials also commonly reported constipation, jitteriness, and increased heart rate. The boxed warning covers abuse, misuse, addiction, overdose, and death. Serious risks include cardiac events in susceptible patients, hypertension, psychosis or mania, serotonin syndrome, seizure, tics, peripheral vasculopathy/Raynaud-like injury, rhabdomyolysis, intestinal ischemia, and prolonged erections.
MAO inhibitors are contraindicated during treatment and within the required 14-day separation, including relevant linezolid or intravenous methylene-blue situations. Serotonergic agents, CYP2D6 inhibitors, other stimulants/sympathomimetics, and seizure-threshold-lowering drugs require review. Acidifying agents can lower amphetamine exposure and alkalinizing agents can raise it; do not manipulate urinary pH to alter the effect. Serious cardiac disease, bipolar or psychotic vulnerability, pregnancy, breastfeeding, tics, substance-use risk, and renal impairment need specific medical consideration.
Stop and obtain urgent assessment for chest pain, unexplained fainting, severe hypertension, seizure, hallucinations, mania, dangerous agitation, hyperthermia or clonus, blue/painful fingers or wounds, severe allergic reaction, severe abdominal pain/bloody stool, or suicidal deterioration. Track pulse, blood pressure, sleep, appetite, weight/growth where relevant, hydration, mood, anxiety, tics, circulation, compulsive behavior, actual work accuracy, and whether the useful window is followed by a disabled evening.
Tolerance to obvious stimulation or euphoria can develop; a less noticeable dose may still be clinically effective. Amphetamine-class misuse, psychological reinforcement, physical dependence, and withdrawal fatigue, hypersomnia, depression, dysphoria, and increased appetite remain possible. The prodrug curve is not an anti-addiction shield, and no enhancement “cycle” makes unsupervised use safe. Prescriber-directed breaks or washouts are clinical decisions.
Use a pharmacy-regulated capsule or chewable tablet, verify the manufacturer and strength, and store it securely. Counterfeit “Vyvanse” has no reliable prodrug identity, and subjective differences between fills cannot establish a quality defect without objective testing.
Bottom Line
Vyvanse can provide a long, quiet bridge from intention to execution when ADHD or binge-eating disorder is the actual impairment. Its defining feature is gradual conversion into dextroamphetamine, which often feels smoother than IR amphetamine but can still suppress food, flatten emotion, prolong insomnia, create rebound, and produce dependence or cardiovascular harm. Smooth does not mean weak, safe for casual enhancement, or capable of choosing the right task.
21.7 Dopamine-Receptor Modulation
21.7.1 What D1 Receptors Do
D1-like receptors help the prefrontal cortex stabilize relevant information and resist distraction. Too little D1 signaling leaves representations weak; too much can lock the system into rigid, narrow processing. A direct agonist turns the receptor on regardless of local dopamine timing, whereas a positive allosteric modulator attempts to amplify dopamine already being released. That distinction may widen control, but it cannot make overshoot impossible.
D1-like receptors help the prefrontal cortex stabilize relevant information and resist distraction. Too little D1 signaling leaves representations weak; too much can lock the system into rigid, narrow processing. A direct agonist turns the receptor on regardless of local dopamine timing, whereas a positive allosteric modulator attempts to amplify dopamine already being released. That distinction may widen control, but it cannot make overshoot impossible.
21.7.2 ASP-4345 — Amplifying D1 Signaling Only When Dopamine Is Present
What it is: ASP-4345 is a discontinued clinical-stage, orally active dopamine D1-receptor positive allosteric modulator (PAM), not a supplement or a direct D1 agonist. Chemically, it is the synthetic small molecule 2-(5-chloro-2-oxo-1,3-benzoxazol-3-yl)-N-methyl-N-[[6-(trifluoromethyl)-1H-benzimidazol-2-yl]methyl]acetamide (C19H14ClF3N4O3). Astellas developed it for cognitive impairment associated with schizophrenia.
What it may feel like: There is no trustworthy recurring phenomenology from healthy users, so the following is a simulation of the mechanism—not a promise. ASP-4345 should not feel like caffeine launching you forward or amphetamine making everything urgent. At rest, it might feel like basically nothing. The intended difference should become visible only when you deliberately load the dorsolateral prefrontal cortex: holding several numbers in mind, comparing competing explanations, keeping the beginning of a long sentence available while reading its end, or stopping an impulse long enough to choose what you actually intended to do.
If the mechanism translated into a useful effect, the mental whiteboard would erase itself less easily. You could hold an active thought in place long enough to rotate it, calculate with it, use it to contain an impulse, or return to it after a distraction instead of watching the entire structure collapse. That matters because working memory is one of the central pillars beneath fluid reasoning. It is also why this compound interested me: the theoretical benefit is not merely feeling focused; it is being able to sustain the deliberate computation from which intelligent control is built. Again, this vivid picture is a mechanistic expectation. Phase I participants did not establish this as a reproducible healthy-user experience.
The simplest description: Imagine the DLPFC as a mental whiteboard and dopamine as the hand writing on it. A direct agonist writes whether or not the brain asked it to; a PAM makes the marks produced by your own active dopamine signal harder to erase. ASP-4345 therefore cannot supply the thought, the dopamine, the metabolic energy, or the decision to use the circuit. It can only amplify a signal already present—and too much amplification can still push the prefrontal cortex past its narrow optimum into rigidity, agitation, worse working memory, or abnormal salience.
How It Works
ASP-4345 binds an allosteric site on the D1 receptor and increases the response to dopamine rather than competing at dopamine’s main binding site. D1 signaling is especially relevant to recurrent prefrontal networks that keep a representation active after the original sight, sound, or instruction has disappeared. That persistent activity is what lets you remember the first number while operating on the second, keep a goal online while an impulse competes with it, or compare several possibilities without losing the earlier ones.
This is activity-dependent in two separate senses. Dopamine must already be released, and the relevant circuit must actually be engaged. If you are lying down scrolling without deliberately holding or manipulating anything, the theoretical cognitive advantage has little useful work to amplify. The DLPFC is also metabolically expensive and vulnerable to sleep loss, severe stress, poor vascular delivery, and other energy bottlenecks; a D1 PAM cannot replace glucose, oxygen, sleep, adequate catecholamine tone, or the act of thinking itself. Finally, D1 performance follows an inverted U: too little produces weak representations, while too much can make them rigid, noisy, or unstable in a different way.
Human cerebrospinal-fluid measurements confirm brain entry. CSF concentrations peaked later than plasma, and CSF-to-unbound-plasma ratios supported CNS penetration. It was nevertheless a systemic oral molecule, not a circuit-selective device; cardiovascular, motor, endocrine, psychiatric, and off-target effects cannot be excluded merely because the desired receptor is in the brain.
Dose and How It Was Studied
Phase I studies used single oral doses of 3–900 mg in healthy adults and repeated once-daily doses of 3–150 mg for 14 days in patients with stable schizophrenia or schizoaffective disorder who were also taking antipsychotics. A later Phase IIa study tested 50 and 150 mg/day as add-on treatment. These are experimental exposures used under ECG, laboratory, psychiatric, and protocol monitoring—not a self-use range. The author supplies no personal dose.
Public formulation-grade water, lipid, and pH-solubility data are inadequate for practical compounding. Trial tablets or capsules created measurable oral exposure, but a vendor’s loose powder cannot inherit their dissolution, stability, or dose uniformity. Food delayed absorption at a studied 300 mg dose but did not materially change the other reported PK parameters; that does not establish a consumer fasting rule.
Timing and Pharmacokinetics
Evidence and Experiences
Phase I studies established oral exposure, brain penetration, and short-term tolerability under controlled conditions. Some exploratory measures suggested possible changes in psychomotor speed, visual attention, or information processing, but these small signals were neither a healthy-adult demonstration nor definitive efficacy. The larger add-on Phase IIa study failed to improve its main cognitive outcome sufficiently, and development stopped.
There is no credible recurring Reddit or forum phenomenology to summarize. That absence should remain visible instead of being filled with predictions such as “clean focus,” “motivation,” or “no overstimulation.” A clinical molecule can have known PK and still have no valid consumer experience profile.
Safety, Interactions, and Monitoring
Short Phase I exposure cannot establish long-term psychiatric, cardiovascular, movement, endocrine, reproductive, or carcinogenic safety. Potential interaction domains include antipsychotics, stimulants, levodopa, dopamine agonists or antagonists, blood-pressure drugs, and other agents affecting dopamine signaling. Because metabolic pathways and interaction studies are incomplete, lack of a listed interaction is not evidence of compatibility.
Stop and obtain assessment for hallucinations, mania, dangerous agitation, severe insomnia, involuntary movement, fainting, chest pain, marked blood-pressure or pulse change, seizure, allergic reaction, or suicidal deterioration. Formal trials monitored ECGs, vital signs, laboratories, suicidality, psychiatric state, and cognition; casual tracking cannot recreate that safety system.
Human tolerance, D1-receptor adaptation, dependence, withdrawal, and repeated healthy-use washout are unknown. No evidence-based cycle exists. Identity and purity are also nontrivial: the clinical compound has a precise structure, while a vendor label does not establish assay, impurities, polymorph, stability, or equivalence to the trial formulation.
Bottom Line
ASP-4345 is one of the most intellectually attractive mechanisms in this guide because it aims at the machinery used to hold and deliberately manipulate thought rather than merely making a person more awake. The imagined payoff is profound: almost nothing at rest, then a stronger mental whiteboard when calculation, inhibition, attention control, or sustained reasoning invokes it. The problem is that the clinical program did not convert that elegant model into established cognitive benefit, and no reliable healthy-user phenomenology exists. It remains a research lesson, not a practical recommendation.
What it is: ASP-4345 is a discontinued clinical-stage, orally active dopamine D1-receptor positive allosteric modulator (PAM), not a supplement or a direct D1 agonist. Chemically, it is the synthetic small molecule 2-(5-chloro-2-oxo-1,3-benzoxazol-3-yl)-N-methyl-N-[[6-(trifluoromethyl)-1H-benzimidazol-2-yl]methyl]acetamide (C19H14ClF3N4O3). Astellas developed it for cognitive impairment associated with schizophrenia.
What it may feel like: There is no trustworthy recurring phenomenology from healthy users, so the following is a simulation of the mechanism—not a promise. ASP-4345 should not feel like caffeine launching you forward or amphetamine making everything urgent. At rest, it might feel like basically nothing. The intended difference should become visible only when you deliberately load the dorsolateral prefrontal cortex: holding several numbers in mind, comparing competing explanations, keeping the beginning of a long sentence available while reading its end, or stopping an impulse long enough to choose what you actually intended to do.
If the mechanism translated into a useful effect, the mental whiteboard would erase itself less easily. You could hold an active thought in place long enough to rotate it, calculate with it, use it to contain an impulse, or return to it after a distraction instead of watching the entire structure collapse. That matters because working memory is one of the central pillars beneath fluid reasoning. It is also why this compound interested me: the theoretical benefit is not merely feeling focused; it is being able to sustain the deliberate computation from which intelligent control is built. Again, this vivid picture is a mechanistic expectation. Phase I participants did not establish this as a reproducible healthy-user experience.
The simplest description: Imagine the DLPFC as a mental whiteboard and dopamine as the hand writing on it. A direct agonist writes whether or not the brain asked it to; a PAM makes the marks produced by your own active dopamine signal harder to erase. ASP-4345 therefore cannot supply the thought, the dopamine, the metabolic energy, or the decision to use the circuit. It can only amplify a signal already present—and too much amplification can still push the prefrontal cortex past its narrow optimum into rigidity, agitation, worse working memory, or abnormal salience.
How It Works
ASP-4345 binds an allosteric site on the D1 receptor and increases the response to dopamine rather than competing at dopamine’s main binding site. D1 signaling is especially relevant to recurrent prefrontal networks that keep a representation active after the original sight, sound, or instruction has disappeared. That persistent activity is what lets you remember the first number while operating on the second, keep a goal online while an impulse competes with it, or compare several possibilities without losing the earlier ones.
This is activity-dependent in two separate senses. Dopamine must already be released, and the relevant circuit must actually be engaged. If you are lying down scrolling without deliberately holding or manipulating anything, the theoretical cognitive advantage has little useful work to amplify. The DLPFC is also metabolically expensive and vulnerable to sleep loss, severe stress, poor vascular delivery, and other energy bottlenecks; a D1 PAM cannot replace glucose, oxygen, sleep, adequate catecholamine tone, or the act of thinking itself. Finally, D1 performance follows an inverted U: too little produces weak representations, while too much can make them rigid, noisy, or unstable in a different way.
Human cerebrospinal-fluid measurements confirm brain entry. CSF concentrations peaked later than plasma, and CSF-to-unbound-plasma ratios supported CNS penetration. It was nevertheless a systemic oral molecule, not a circuit-selective device; cardiovascular, motor, endocrine, psychiatric, and off-target effects cannot be excluded merely because the desired receptor is in the brain.
Dose and How It Was Studied
Phase I studies used single oral doses of 3–900 mg in healthy adults and repeated once-daily doses of 3–150 mg for 14 days in patients with stable schizophrenia or schizoaffective disorder who were also taking antipsychotics. A later Phase IIa study tested 50 and 150 mg/day as add-on treatment. These are experimental exposures used under ECG, laboratory, psychiatric, and protocol monitoring—not a self-use range. The author supplies no personal dose.
Public formulation-grade water, lipid, and pH-solubility data are inadequate for practical compounding. Trial tablets or capsules created measurable oral exposure, but a vendor’s loose powder cannot inherit their dissolution, stability, or dose uniformity. Food delayed absorption at a studied 300 mg dose but did not materially change the other reported PK parameters; that does not establish a consumer fasting rule.
Timing and Pharmacokinetics
- Subjective onset: Unknown; trials did not establish a recognizable healthy-user sensation.
- Pharmacologic onset: Plasma concentration rose rapidly after oral dosing, with CNS entry following.
- Tmax: Median plasma Tmax was approximately 1.0–2.26 hours after single fasted doses and 1.25–3.02 hours at repeated-dose steady state. At 300 mg, food shifted median Tmax from 1.5 to 4 hours. CSF Tmax ranged about 2.48–7.98 hours.
- Absorption/bioavailability: Oral absorption is demonstrated, but absolute human bioavailability is not publicly established. Exposure increased less than dose-proportionally across the unusually broad experimental range.
- Full practical effect: Unknown. Fourteen-day Phase I cognitive signals were exploratory, and the subsequent Phase II program failed to establish meaningful cognitive efficacy.
- Subjective duration: Unknown; plasma persistence does not tell us what a healthy person would feel.
- Half-life: About 9.1–14.3 hours after single doses and 11.1–26.8 hours in the repeated-dose patient study.
- Accumulation/steady state: Repeated once-daily exposure reached a study-defined steady state; the half-life range implies most ordinary accumulation would develop over roughly three to six days, but product- and dose-specific accumulation was not converted into a consumer rule.
- Near-complete elimination: A defensible five-half-life estimate is roughly two to six days, using the observed human range. Receptor-level or behavioral aftereffects were not characterized.
- Metabolism/elimination: Public human data are insufficient to give a dependable CYP, active-metabolite, renal, or fecal interaction map. That missing information is itself a major self-experimentation problem.
Evidence and Experiences
Phase I studies established oral exposure, brain penetration, and short-term tolerability under controlled conditions. Some exploratory measures suggested possible changes in psychomotor speed, visual attention, or information processing, but these small signals were neither a healthy-adult demonstration nor definitive efficacy. The larger add-on Phase IIa study failed to improve its main cognitive outcome sufficiently, and development stopped.
There is no credible recurring Reddit or forum phenomenology to summarize. That absence should remain visible instead of being filled with predictions such as “clean focus,” “motivation,” or “no overstimulation.” A clinical molecule can have known PK and still have no valid consumer experience profile.
Safety, Interactions, and Monitoring
Short Phase I exposure cannot establish long-term psychiatric, cardiovascular, movement, endocrine, reproductive, or carcinogenic safety. Potential interaction domains include antipsychotics, stimulants, levodopa, dopamine agonists or antagonists, blood-pressure drugs, and other agents affecting dopamine signaling. Because metabolic pathways and interaction studies are incomplete, lack of a listed interaction is not evidence of compatibility.
Stop and obtain assessment for hallucinations, mania, dangerous agitation, severe insomnia, involuntary movement, fainting, chest pain, marked blood-pressure or pulse change, seizure, allergic reaction, or suicidal deterioration. Formal trials monitored ECGs, vital signs, laboratories, suicidality, psychiatric state, and cognition; casual tracking cannot recreate that safety system.
Human tolerance, D1-receptor adaptation, dependence, withdrawal, and repeated healthy-use washout are unknown. No evidence-based cycle exists. Identity and purity are also nontrivial: the clinical compound has a precise structure, while a vendor label does not establish assay, impurities, polymorph, stability, or equivalence to the trial formulation.
Bottom Line
ASP-4345 is one of the most intellectually attractive mechanisms in this guide because it aims at the machinery used to hold and deliberately manipulate thought rather than merely making a person more awake. The imagined payoff is profound: almost nothing at rest, then a stronger mental whiteboard when calculation, inhibition, attention control, or sustained reasoning invokes it. The problem is that the clinical program did not convert that elegant model into established cognitive benefit, and no reliable healthy-user phenomenology exists. It remains a research lesson, not a practical recommendation.
21.8 Monoamine-Oxidase Modulation
21.8.1 Selegiline / Deprenyl — A Short-Lived Drug That Disables an Enzyme for Days
What it is: Selegiline (L-deprenyl) is a lipophilic propargylamine that irreversibly inhibits monoamine oxidase B (MAO-B) at conventional Parkinson’s exposure. It is available as swallowed tablets/capsules, the Zelapar orally disintegrating tablet (ODT), and the Emsam transdermal antidepressant patch. Route is not a cosmetic detail: it changes parent-drug exposure, amphetamine metabolites, selectivity, food rules, half-life, and interaction risk.
What it may feel like: The low-oral-dose effect may be almost invisible: a little less friction starting tasks, slightly greater wakefulness, libido, curiosity, or emotional color. Some report a conspicuous first-week “honeymoon” of motivation and creativity that settles into a quieter baseline. Others feel nothing, while a sensitive user may get insomnia, irritability, pressured confidence, anxiety, jaw tension, hypomania, or paranoia. The antidepressant patch is a different exposure and can produce a broader mood/energy effect over weeks rather than a tiny acute dopamine lift.
The simplest description: MAO enzymes are disposal machines for monoamines. Selegiline permanently disables each MAO-B molecule it reaches; even though the parent drug leaves plasma quickly, the body must manufacture new enzyme before the effect fully disappears. This is why judging safety from the two-hour parent half-life is like saying a locksmith is gone while ignoring that the lock was removed.
How It Works
At conventional swallowed Parkinson’s doses, selegiline preferentially inhibits MAO-B, reducing breakdown of dopamine and phenethylamine and extending levodopa’s effect. As systemic exposure rises, functional selectivity erodes and MAO-A inhibition becomes important, broadening effects to serotonin and norepinephrine and increasing tyramine/interaction risk. Irreversible inhibition means pharmacodynamics outlast plasma concentrations.
The molecule readily crosses the blood-brain barrier but is not CNS-only. Swallowed selegiline undergoes extensive first-pass metabolism to desmethylselegiline, levomethamphetamine, and levoamphetamine—the levorotatory isomers, not recreational d-methamphetamine. ODT and transdermal delivery reduce first-pass metabolite exposure and raise parent exposure. Central benefit can therefore coexist with orthostasis, blood-pressure changes, insomnia, gastrointestinal effects, and dangerous drug/food interactions.
Dose and How It Is Taken
Swallowed selegiline labeling for Parkinson’s disease commonly uses 5 mg with breakfast and 5 mg with lunch as levodopa adjunct therapy. Zelapar begins at 1.25 mg once daily before breakfast, with a labeled 2.5 mg/day ceiling; Emsam begins at 6 mg delivered per 24 hours, with 9 and 12 mg/24 h prescription steps for major depression. These routes and milligrams are not interchangeable, and none is a healthy-user schedule. The author supplies no personal dose.
Selegiline free base is lipophilic; pharmaceutical hydrochloride forms and delivery systems are engineered for their route. Swallowed product follows its label. Zelapar dissolves on the tongue and requires no food or liquid for five minutes before and after, because food cuts parent Cmax/AUC to about 60% of fasted exposure. Emsam is applied once daily to approved intact-skin sites; heat can increase absorption, and patches must not be cut. Compounded “sublingual selegiline” cannot automatically inherit Zelapar’s PK.
Timing and Pharmacokinetics
Evidence and Experiences
Clinical evidence supports adjunctive use in Parkinson’s disease and the transdermal system for major depressive disorder. It does not demonstrate human longevity, dopamine-neuron preservation, or routine cognitive enhancement in healthy young adults. Evidence from one route cannot be transferred cleanly to another because parent and metabolite exposure differ.
Recurring reports match that route dependence and also expose major selection bias. Some low-dose users describe greater motivation, libido, wakefulness, creativity, or less anhedonia; others report no durable effect after an early honeymoon. Negative accounts describe insomnia that persists after the dose, irritability, anger, overconfidence, fast speech, hypomania, or paranoia emerging over weeks. Stimulant and caffeine combinations are repeatedly described as stronger than expected. These are anecdotes, not safe-dose validation. Mixed motivation, creativity, libido, insomnia, and nonresponse · Initial motivation versus a new baseline · Irritability, insomnia, and paranoia causing discontinuation · Broader behavioral account including overconfidence · Emsam reports from clinical depression
Safety, Interactions, and Monitoring
Common route-dependent effects include nausea, dry mouth, dizziness/orthostasis, headache, insomnia, vivid dreams, agitation, dyskinesia or hallucinations in Parkinson’s treatment, and patch-site reactions with Emsam. Serious hazards include serotonin syndrome, hypertensive crisis, severe blood-pressure elevation, mania, psychosis, suicidality, and accidental interaction. In Emsam trials, mania/hypomania occurred in about 0.4%; antidepressant suicidality warnings apply particularly to adolescents and young adults.
Do not improvise combinations with SSRIs, SNRIs, clomipramine/imipramine, other MAOIs, dextromethorphan, tramadol, meperidine, methadone, certain other opioids, serotonergic agents, stimulants, sympathomimetic decongestants, buspirone, or linezolid. Formal route-specific contraindications and washouts control. Tyramine restrictions are required for Emsam 9 and 12 mg/24 h and for nonselective MAO exposure; Emsam 6 mg/24 h has a different labeled diet rule. A low swallowed dose today does not prove that an altered sublingual route or higher dose remains MAO-B-selective.
Seek emergency care for a sudden severe headache, marked hypertension, chest pain, high fever, sweating with agitation/confusion, clonus, rigidity, seizure, fainting, mania, psychosis, or suicidal crisis. Track seated/standing blood pressure, pulse, sleep, mood activation, irritability, impulse control, levodopa adverse effects where relevant, every prescription/OTC drug, and diet when the route/exposure requires it.
Subjective novelty may fade, but irreversible inhibition is not ordinary tolerance. Behavioral reliance, sleep debt, psychiatric activation, and altered baseline can still develop. There is no evidence-based longevity/nootropic cycle. Only route-specific regulated prescription products can be tied to published PK; patch heat exposure, cut patches, or unverified compounded liquids defeat that assurance.
Bottom Line
Selegiline’s appeal is real: it can make dopamine signaling last longer without the same acute release profile as amphetamine. Its trap is equally real: a short-lived parent drug creates multi-day enzyme inhibition, and route changes everything. It can be clinically valuable in Parkinson’s disease or depression, but interaction complexity, insomnia, mood activation, and uncertain healthy-user benefit make casual nootropic use poor-risk.
What it is: Selegiline (L-deprenyl) is a lipophilic propargylamine that irreversibly inhibits monoamine oxidase B (MAO-B) at conventional Parkinson’s exposure. It is available as swallowed tablets/capsules, the Zelapar orally disintegrating tablet (ODT), and the Emsam transdermal antidepressant patch. Route is not a cosmetic detail: it changes parent-drug exposure, amphetamine metabolites, selectivity, food rules, half-life, and interaction risk.
What it may feel like: The low-oral-dose effect may be almost invisible: a little less friction starting tasks, slightly greater wakefulness, libido, curiosity, or emotional color. Some report a conspicuous first-week “honeymoon” of motivation and creativity that settles into a quieter baseline. Others feel nothing, while a sensitive user may get insomnia, irritability, pressured confidence, anxiety, jaw tension, hypomania, or paranoia. The antidepressant patch is a different exposure and can produce a broader mood/energy effect over weeks rather than a tiny acute dopamine lift.
The simplest description: MAO enzymes are disposal machines for monoamines. Selegiline permanently disables each MAO-B molecule it reaches; even though the parent drug leaves plasma quickly, the body must manufacture new enzyme before the effect fully disappears. This is why judging safety from the two-hour parent half-life is like saying a locksmith is gone while ignoring that the lock was removed.
How It Works
At conventional swallowed Parkinson’s doses, selegiline preferentially inhibits MAO-B, reducing breakdown of dopamine and phenethylamine and extending levodopa’s effect. As systemic exposure rises, functional selectivity erodes and MAO-A inhibition becomes important, broadening effects to serotonin and norepinephrine and increasing tyramine/interaction risk. Irreversible inhibition means pharmacodynamics outlast plasma concentrations.
The molecule readily crosses the blood-brain barrier but is not CNS-only. Swallowed selegiline undergoes extensive first-pass metabolism to desmethylselegiline, levomethamphetamine, and levoamphetamine—the levorotatory isomers, not recreational d-methamphetamine. ODT and transdermal delivery reduce first-pass metabolite exposure and raise parent exposure. Central benefit can therefore coexist with orthostasis, blood-pressure changes, insomnia, gastrointestinal effects, and dangerous drug/food interactions.
Dose and How It Is Taken
Swallowed selegiline labeling for Parkinson’s disease commonly uses 5 mg with breakfast and 5 mg with lunch as levodopa adjunct therapy. Zelapar begins at 1.25 mg once daily before breakfast, with a labeled 2.5 mg/day ceiling; Emsam begins at 6 mg delivered per 24 hours, with 9 and 12 mg/24 h prescription steps for major depression. These routes and milligrams are not interchangeable, and none is a healthy-user schedule. The author supplies no personal dose.
Selegiline free base is lipophilic; pharmaceutical hydrochloride forms and delivery systems are engineered for their route. Swallowed product follows its label. Zelapar dissolves on the tongue and requires no food or liquid for five minutes before and after, because food cuts parent Cmax/AUC to about 60% of fasted exposure. Emsam is applied once daily to approved intact-skin sites; heat can increase absorption, and patches must not be cut. Compounded “sublingual selegiline” cannot automatically inherit Zelapar’s PK.
Timing and Pharmacokinetics
- Subjective onset: Acute activation can appear within hours or the first several days; Parkinson’s adjunct effects can occur early, while antidepressant benefit generally develops over two to six weeks.
- Pharmacologic onset: MAO-B inhibition begins after the first exposure and deepens with repeated dosing.
- Tmax: Swallowed 5 mg tablets reach parent Tmax in roughly 40–90 minutes. Zelapar reaches Tmax in 10–15 minutes. A patch produces continuous delivery rather than a useful single peak.
- Absorption/bioavailability: Absolute swallowed bioavailability is unknown and low/variable because of extensive gut/liver first pass. Dose-normalized parent exposure is higher with Zelapar; Emsam delivers about 25–30% of patch content systemically over 24 hours, with a broad 10–40% range.
- Full practical effect: Parkinson’s/levodopa response can change quickly, but a stable enzyme-inhibition pattern takes repeated dosing. Emsam antidepressant efficacy is judged over weeks, not the first stimulating day.
- Subjective duration: Activation may last much of a day and sleep effects can last into the next night. Enzyme inhibition persists for days even after the felt effect ends.
- Half-life: Swallowed parent half-life is about two hours after a single dose; single-dose Zelapar is about 1.3 hours, rising to a median 10 hours at steady state. With Emsam, mean parent/metabolite half-lives range roughly 18–25 hours.
- Accumulation/steady state: Zelapar and swallowed tablets accumulate with repeated dosing, with labeled steady state after about eight days. Emsam reaches a stable daily profile during repeated application.
- Near-complete elimination/washout: Parent/metabolites vary by route, but functional MAO inhibition is the decisive clock. Platelet MAO-B returns toward normal in roughly five to seven days after oral selegiline; formal Emsam interaction labeling generally requires two weeks after stopping before a contraindicated drug, and at least five weeks after fluoxetine before Emsam. These are not interchangeable DIY washouts.
- Metabolism/elimination: Multiple CYP enzymes form desmethylselegiline, levomethamphetamine, and levoamphetamine; urinary elimination is mainly as metabolites. Route determines how much first-pass metabolite appears.
Evidence and Experiences
Clinical evidence supports adjunctive use in Parkinson’s disease and the transdermal system for major depressive disorder. It does not demonstrate human longevity, dopamine-neuron preservation, or routine cognitive enhancement in healthy young adults. Evidence from one route cannot be transferred cleanly to another because parent and metabolite exposure differ.
Recurring reports match that route dependence and also expose major selection bias. Some low-dose users describe greater motivation, libido, wakefulness, creativity, or less anhedonia; others report no durable effect after an early honeymoon. Negative accounts describe insomnia that persists after the dose, irritability, anger, overconfidence, fast speech, hypomania, or paranoia emerging over weeks. Stimulant and caffeine combinations are repeatedly described as stronger than expected. These are anecdotes, not safe-dose validation. Mixed motivation, creativity, libido, insomnia, and nonresponse · Initial motivation versus a new baseline · Irritability, insomnia, and paranoia causing discontinuation · Broader behavioral account including overconfidence · Emsam reports from clinical depression
Safety, Interactions, and Monitoring
Common route-dependent effects include nausea, dry mouth, dizziness/orthostasis, headache, insomnia, vivid dreams, agitation, dyskinesia or hallucinations in Parkinson’s treatment, and patch-site reactions with Emsam. Serious hazards include serotonin syndrome, hypertensive crisis, severe blood-pressure elevation, mania, psychosis, suicidality, and accidental interaction. In Emsam trials, mania/hypomania occurred in about 0.4%; antidepressant suicidality warnings apply particularly to adolescents and young adults.
Do not improvise combinations with SSRIs, SNRIs, clomipramine/imipramine, other MAOIs, dextromethorphan, tramadol, meperidine, methadone, certain other opioids, serotonergic agents, stimulants, sympathomimetic decongestants, buspirone, or linezolid. Formal route-specific contraindications and washouts control. Tyramine restrictions are required for Emsam 9 and 12 mg/24 h and for nonselective MAO exposure; Emsam 6 mg/24 h has a different labeled diet rule. A low swallowed dose today does not prove that an altered sublingual route or higher dose remains MAO-B-selective.
Seek emergency care for a sudden severe headache, marked hypertension, chest pain, high fever, sweating with agitation/confusion, clonus, rigidity, seizure, fainting, mania, psychosis, or suicidal crisis. Track seated/standing blood pressure, pulse, sleep, mood activation, irritability, impulse control, levodopa adverse effects where relevant, every prescription/OTC drug, and diet when the route/exposure requires it.
Subjective novelty may fade, but irreversible inhibition is not ordinary tolerance. Behavioral reliance, sleep debt, psychiatric activation, and altered baseline can still develop. There is no evidence-based longevity/nootropic cycle. Only route-specific regulated prescription products can be tied to published PK; patch heat exposure, cut patches, or unverified compounded liquids defeat that assurance.
Bottom Line
Selegiline’s appeal is real: it can make dopamine signaling last longer without the same acute release profile as amphetamine. Its trap is equally real: a short-lived parent drug creates multi-day enzyme inhibition, and route changes everything. It can be clinically valuable in Parkinson’s disease or depression, but interaction complexity, insomnia, mood activation, and uncertain healthy-user benefit make casual nootropic use poor-risk.
21.9 Indirect Dopaminergic Support
21.9.1 Uridine Monophosphate + DHA + Choline — Membrane-Building Substrates, Not Acute Dopamine
What it is: This is a three-part nutrient stack rather than one compound: uridine monophosphate supplies a uridine source, DHA supplies a long-chain omega-3 fatty acid, and choline supplies a phospholipid and acetylcholine precursor. Clinical medical-food formulas such as Fortasyn Connect include additional nutrients and cannot be reduced to these three ingredients without changing the intervention.
What it may feel like: Most readers should expect no acute “dopamine” sensation. Positive reports describe subtle improvement in verbal flow, mood, memory, or mental continuity after repeated use; others notice fishy reflux, headache, low mood from excess cholinergic tone, GI upset, or nothing. If it works, the vivid result is more like having better-quality building material available during renovation than flipping on brighter lights today.
The simplest description: The stack supplies raw materials for neuronal membranes, but raw materials do not command the brain to build a useful synapse or guarantee better cognition.
How It Works
Uridine can support CTP-dependent phosphatidylcholine synthesis, choline supplies another Kennedy-pathway substrate, and DHA becomes part of neuronal membranes. Preclinical work suggests the combination can increase phosphatide and synaptic-marker formation when precursor availability is limiting. It may also influence neurotransmission indirectly, but it is not an acute dopamine releaser. DHA readily participates in brain lipid pools over time; uridine and choline have central relevance, yet the stack is systemic and also affects liver, plasma lipids, methylation, platelets, and peripheral membranes.
Dose and How It Was Studied
The clearest human evidence comes from fixed medical-food formulas used daily for 12–24 weeks or longer in mild Alzheimer disease or prodromal populations. Those products include UMP, DHA, choline or phospholipids, EPA, B vitamins, antioxidants, and other cofactors in exact amounts. Their results do not establish a home-built three-ingredient dose for healthy students, and the author supplies no universal stack dose here.
UMP and many choline salts are water-compatible; DHA is lipid-soluble and belongs in a stable, oxidation-tested oil taken with a meal containing fat. The components therefore should not be forced into one empty-stomach rule. A finished medical food is taken as formulated, while separate products require separate identity, storage, and administration.
Timing and Pharmacokinetics
Evidence and Experiences
Mechanistic and animal evidence supports substrate-dependent membrane synthesis. Human trials concern complete medical-food formulas in impaired older populations, with mixed results across disease stage and outcome. They do not isolate the three components or establish healthy-young enhancement, and a plasma nutrient rise is not proof that useful synapses were formed.
Forum reports are strongly confounded by stacks and product forms. Recurring claims include subtle mood or verbal benefits after weeks, while negative reports include headache, depression or irritability attributed to cholinergic load, fishy reflux, and nonresponse. These cannot be separated cleanly from baseline diet, omega-3 status, choline form, or other nootropics. Stack discussion
Safety, Interactions, and Monitoring
DHA products can cause reflux, GI upset, and bleeding concerns at high exposure or with anticoagulants; choline can cause GI symptoms, fishy odor, headache, low mood, or hypotension depending on form and exposure; uridine safety at chronic supplement doses is less established than ordinary dietary exposure. Stop for unusual bleeding, severe mood deterioration, allergy, persistent vomiting, fainting, or significant neurologic change. Anticoagulants, antiplatelets, cholinergic drugs, bipolar vulnerability, liver disease, pregnancy, and complex metabolic treatment require review.
Human tolerance and dependence are not established, and no evidence-based cycling schedule exists. Require pharmaceutical- or food-grade UMP identity, a named choline form, DHA oxidation and contaminant testing, and cold/dark storage appropriate to the oil. Track the exact product, diet, delayed recall, study output, mood, headache, GI effects, fishy odor, bruising, and whether any benefit persists during a planned washout.
Bottom Line
This is a slow membrane-substrate hypothesis, not an acute dopaminergic nootropic. It is most defensible as a defined nutritional or medical-food intervention when precursor status may be limiting; it is not evidence that three loose supplements will make a healthy young brain build better circuits.
What it is: This is a three-part nutrient stack rather than one compound: uridine monophosphate supplies a uridine source, DHA supplies a long-chain omega-3 fatty acid, and choline supplies a phospholipid and acetylcholine precursor. Clinical medical-food formulas such as Fortasyn Connect include additional nutrients and cannot be reduced to these three ingredients without changing the intervention.
What it may feel like: Most readers should expect no acute “dopamine” sensation. Positive reports describe subtle improvement in verbal flow, mood, memory, or mental continuity after repeated use; others notice fishy reflux, headache, low mood from excess cholinergic tone, GI upset, or nothing. If it works, the vivid result is more like having better-quality building material available during renovation than flipping on brighter lights today.
The simplest description: The stack supplies raw materials for neuronal membranes, but raw materials do not command the brain to build a useful synapse or guarantee better cognition.
How It Works
Uridine can support CTP-dependent phosphatidylcholine synthesis, choline supplies another Kennedy-pathway substrate, and DHA becomes part of neuronal membranes. Preclinical work suggests the combination can increase phosphatide and synaptic-marker formation when precursor availability is limiting. It may also influence neurotransmission indirectly, but it is not an acute dopamine releaser. DHA readily participates in brain lipid pools over time; uridine and choline have central relevance, yet the stack is systemic and also affects liver, plasma lipids, methylation, platelets, and peripheral membranes.
Dose and How It Was Studied
The clearest human evidence comes from fixed medical-food formulas used daily for 12–24 weeks or longer in mild Alzheimer disease or prodromal populations. Those products include UMP, DHA, choline or phospholipids, EPA, B vitamins, antioxidants, and other cofactors in exact amounts. Their results do not establish a home-built three-ingredient dose for healthy students, and the author supplies no universal stack dose here.
UMP and many choline salts are water-compatible; DHA is lipid-soluble and belongs in a stable, oxidation-tested oil taken with a meal containing fat. The components therefore should not be forced into one empty-stomach rule. A finished medical food is taken as formulated, while separate products require separate identity, storage, and administration.
Timing and Pharmacokinetics
- Subjective onset: Usually absent acutely; anecdotal changes, when reported, develop over days to weeks.
- Pharmacologic onset / Tmax: Each component peaks on a different schedule. Oral uridine can raise plasma uridine within hours, while choline forms and DHA formulations vary; there is no unified stack Tmax.
- Absorption/bioavailability: All three are orally available through different pathways, but no single bioavailability value describes the stack. DHA absorption improves with formulation and dietary fat.
- Full practical effect: Clinical formulas evaluate memory or functional effects over 12–24 weeks, not one study session.
- Subjective duration: No clean daily window; DHA membrane incorporation and nutrient-pool changes outlast plasma peaks.
- Half-life: No single stack half-life exists. Plasma uridine, choline metabolites, and DHA-containing lipids have different clocks ranging from hours to much longer tissue turnover.
- Accumulation/steady state: DHA and membrane pools accumulate over weeks, while uridine and choline exposure turns over faster; a unified steady state is not meaningful.
- Near-complete elimination: Cannot be represented by one number because incorporated DHA and phospholipids are normal tissue components with long turnover.
- Metabolism/elimination: UMP is dephosphorylated and enters pyrimidine metabolism, DHA enters lipid transport and membrane pathways, and choline enters acetylcholine, methylation, oxidation, and phosphatidylcholine synthesis.
Evidence and Experiences
Mechanistic and animal evidence supports substrate-dependent membrane synthesis. Human trials concern complete medical-food formulas in impaired older populations, with mixed results across disease stage and outcome. They do not isolate the three components or establish healthy-young enhancement, and a plasma nutrient rise is not proof that useful synapses were formed.
Forum reports are strongly confounded by stacks and product forms. Recurring claims include subtle mood or verbal benefits after weeks, while negative reports include headache, depression or irritability attributed to cholinergic load, fishy reflux, and nonresponse. These cannot be separated cleanly from baseline diet, omega-3 status, choline form, or other nootropics. Stack discussion
Safety, Interactions, and Monitoring
DHA products can cause reflux, GI upset, and bleeding concerns at high exposure or with anticoagulants; choline can cause GI symptoms, fishy odor, headache, low mood, or hypotension depending on form and exposure; uridine safety at chronic supplement doses is less established than ordinary dietary exposure. Stop for unusual bleeding, severe mood deterioration, allergy, persistent vomiting, fainting, or significant neurologic change. Anticoagulants, antiplatelets, cholinergic drugs, bipolar vulnerability, liver disease, pregnancy, and complex metabolic treatment require review.
Human tolerance and dependence are not established, and no evidence-based cycling schedule exists. Require pharmaceutical- or food-grade UMP identity, a named choline form, DHA oxidation and contaminant testing, and cold/dark storage appropriate to the oil. Track the exact product, diet, delayed recall, study output, mood, headache, GI effects, fishy odor, bruising, and whether any benefit persists during a planned washout.
Bottom Line
This is a slow membrane-substrate hypothesis, not an acute dopaminergic nootropic. It is most defensible as a defined nutritional or medical-food intervention when precursor status may be limiting; it is not evidence that three loose supplements will make a healthy young brain build better circuits.
21.9.2 9-Methyl-β-Carboline / 9-Me-BC — Fascinating Dopamine Biology With Zero Human Pharmacokinetics
What it is: 9-Methyl-β-carboline (9-Me-BC; C12H10N2) is a synthetic, neutral fused heteroaromatic β-carboline research chemical. Cell and animal experiments report dopaminergic differentiation, neurite growth, altered neurotrophic-gene expression, mitochondrial effects, MAO inhibition, and protection in selected toxin models. No controlled human trial has established a dose, PK profile, benefit, or long-term safety.
What it may feel like: Sparse reports describe a gradual return of wanting: music becomes interesting, ordinary tasks stop feeling dead, caffeine feels stronger, or addictive urges become less dominant. Others feel only mild stimulation, anxiety, insomnia, headache, reduced libido, emotional change, or absolutely nothing. This is not a clean “dopamine restoration” signature. Many reports coincide with stimulant abstinence, recovery from anhedonia, multiple stacks, extreme light avoidance, and unverified powder, so spontaneous recovery and expectation are powerful confounds.
The simplest description: Preclinical 9-Me-BC is less like pouring dopamine into the brain and more like altering the workshop that maintains dopamine neurons—gene expression, trophic signals, mitochondrial function, and monoamine breakdown. The problem is that every impressive result occurred in a dish or animal. A compound can help injured rodent neurons and still be ineffective, toxic, photoreactive, or metabolized into something different in humans.
How It Works
In mesencephalic cultures, 9-Me-BC increased tyrosine-hydroxylase-positive cells and neurite growth and altered neurotrophic-factor expression. Animal work reported restoration in a toxin-based Parkinsonian model and changes in dopamine, mitochondrial respiratory-chain performance, dendrites, and synapses. It also inhibits MAO-A and MAO-B in vitro, with greater potency reported at MAO-A in some assays. These are multiple hypotheses, not proof that it regenerates human dopamine neurons.
Animal activity suggests CNS exposure, but human blood-brain-barrier penetration, tissue distribution, central/peripheral balance, receptor selectivity, and metabolites are unknown. β-Carboline chemistry also creates hazards that “neuroprotective” marketing leaves out: related and specifically studied N-methyl β-carbolines can photosensitize and damage DNA under irradiation in cell-free/cellular experimental systems. The magnitude of human skin, eye, or systemic risk is unknown—not proven harmless and not equivalent to a demonstrated clinical cancer risk.
Dose and How It Was Studied
There is no human studied or labeled dose and the author supplies no personal dose. Forum ranges and oral, sublingual, intranasal, or rectal routines are uncontrolled experiments, not dose-finding evidence. Including those numbers as instructions would create precision where none exists.
9-Me-BC is relatively lipophilic and poorly compatible with water; formulation-grade pH-solubility, dissolution, stability, and oral bioavailability data are not available. This means “take it fasted,” “hold it under the tongue,” and homemade-solvent advice cannot be validated. A bitter powder dissolving in a solvent proves neither absorption nor identity and may introduce local injury or residual-solvent exposure.
Timing and Pharmacokinetics
Evidence and Experiences
Evidence is entirely preclinical for efficacy. Cell counts, tyrosine-hydroxylase expression, rodent toxin models, and mitochondrial assays cannot establish improved motivation, reversal of stimulant injury, addiction treatment, or safety in a healthy human. There are no human effect sizes, incidence rates, dose-response curves, or long-term follow-ups.
Forum reports are scarce but not nonexistent. Positive accounts describe mild/gentle motivation, restored reward sensitivity, or gradual relief from stimulant-associated anhedonia. Negative and null accounts include no change after several days, anxiety, sleep disturbance, headache, libido changes, and reports of unusually easy sunburn. Users’ “Dracula” light-avoidance protocols show that the photochemical concern influences behavior; they do not validate a safe UV threshold or washout. Mixed and scarce user experiences · Motivation alongside reported sun sensitivity and libido change · Stimulant-anhedonia account with major confounding · No useful effect after several days · Gradual improvement but no clean attribution
Safety, Interactions, and Monitoring
There is no human adverse-event incidence. Major unresolved domains include phototoxicity/photogenotoxicity, retinal exposure, long-term neurotoxicity, genotoxicity/carcinogenicity, reproductive and developmental toxicity, liver/kidney effects, movement changes, and psychiatric activation. The correct conclusion from missing toxicology is unknown risk, not “no reported deaths.”
Because 9-Me-BC inhibits both MAO isoforms in vitro, combining it with MAOIs, SSRIs/SNRIs, other serotonergic drugs, 5-HTP, stimulants, levodopa, dopamine agonists, dextromethorphan, tramadol, sympathomimetics, or tyramine-rich exposure could be dangerous in principle. No human study tells us whether those classic MAOI interactions occur at forum exposures or how long to separate them. Avoiding a few foods or sunlight does not solve unknown systemic pharmacology.
Stop and obtain medical assessment for a burn/rash or eye symptoms after light, severe headache, marked hypertension, agitation, confusion, hyperthermia, clonus/rigidity, hallucinations, mania, seizure, movement change, jaundice/dark urine, severe abdominal symptoms, or suicidal deterioration. Pulse, blood pressure, sleep, mood, skin/eye symptoms, and objective function could be tracked, but monitoring cannot make an uncharacterized research chemical safe or establish its disappearance.
Human tolerance, dependence, withdrawal, receptor adaptation, cycling, and washout are unknown. Require independent identity, assay, impurity, residual-solvent, heavy-metal, and degradation testing even for research—and recognize that analytical purity still cannot establish human safety. Pregnancy, adolescence, psychiatric illness, cardiovascular disease, photosensitivity, eye disease, and liver/kidney impairment have no established safe-use basis.
Bottom Line
9-Me-BC has one of the most interesting preclinical dopamine stories in this guide and one of the weakest human foundations: zero controlled human efficacy and zero usable human PK. Reports of restored motivation are worth recording as anecdotes, not promoting as regeneration. Unknown metabolism, MAO interactions, and real experimental photochemical warning signals make the self-experimentation risk-benefit unfavorable.
What it is: 9-Methyl-β-carboline (9-Me-BC; C12H10N2) is a synthetic, neutral fused heteroaromatic β-carboline research chemical. Cell and animal experiments report dopaminergic differentiation, neurite growth, altered neurotrophic-gene expression, mitochondrial effects, MAO inhibition, and protection in selected toxin models. No controlled human trial has established a dose, PK profile, benefit, or long-term safety.
What it may feel like: Sparse reports describe a gradual return of wanting: music becomes interesting, ordinary tasks stop feeling dead, caffeine feels stronger, or addictive urges become less dominant. Others feel only mild stimulation, anxiety, insomnia, headache, reduced libido, emotional change, or absolutely nothing. This is not a clean “dopamine restoration” signature. Many reports coincide with stimulant abstinence, recovery from anhedonia, multiple stacks, extreme light avoidance, and unverified powder, so spontaneous recovery and expectation are powerful confounds.
The simplest description: Preclinical 9-Me-BC is less like pouring dopamine into the brain and more like altering the workshop that maintains dopamine neurons—gene expression, trophic signals, mitochondrial function, and monoamine breakdown. The problem is that every impressive result occurred in a dish or animal. A compound can help injured rodent neurons and still be ineffective, toxic, photoreactive, or metabolized into something different in humans.
How It Works
In mesencephalic cultures, 9-Me-BC increased tyrosine-hydroxylase-positive cells and neurite growth and altered neurotrophic-factor expression. Animal work reported restoration in a toxin-based Parkinsonian model and changes in dopamine, mitochondrial respiratory-chain performance, dendrites, and synapses. It also inhibits MAO-A and MAO-B in vitro, with greater potency reported at MAO-A in some assays. These are multiple hypotheses, not proof that it regenerates human dopamine neurons.
Animal activity suggests CNS exposure, but human blood-brain-barrier penetration, tissue distribution, central/peripheral balance, receptor selectivity, and metabolites are unknown. β-Carboline chemistry also creates hazards that “neuroprotective” marketing leaves out: related and specifically studied N-methyl β-carbolines can photosensitize and damage DNA under irradiation in cell-free/cellular experimental systems. The magnitude of human skin, eye, or systemic risk is unknown—not proven harmless and not equivalent to a demonstrated clinical cancer risk.
Dose and How It Was Studied
There is no human studied or labeled dose and the author supplies no personal dose. Forum ranges and oral, sublingual, intranasal, or rectal routines are uncontrolled experiments, not dose-finding evidence. Including those numbers as instructions would create precision where none exists.
9-Me-BC is relatively lipophilic and poorly compatible with water; formulation-grade pH-solubility, dissolution, stability, and oral bioavailability data are not available. This means “take it fasted,” “hold it under the tongue,” and homemade-solvent advice cannot be validated. A bitter powder dissolving in a solvent proves neither absorption nor identity and may introduce local injury or residual-solvent exposure.
Timing and Pharmacokinetics
- Subjective onset: Unknown scientifically. Anecdotes range from subtle same-day stimulation to gradual change over several days or weeks, with many nonresponders.
- Pharmacologic onset: Unknown in humans; cell-culture gene-expression and differentiation effects developed across many hours to days and cannot define human onset.
- Tmax: Unknown in humans for every proposed route.
- Absorption/bioavailability: Human oral, buccal, nasal, and rectal absorption and absolute bioavailability are unknown.
- Full practical effect: Unknown. Forum claims of a cumulative effect over one to several weeks have not been tested against placebo or objective recovery trajectories.
- Subjective duration: Unknown; reports of same-day stimulation and persistent post-course change cannot be separated from adaptation, abstinence, sleep, or expectation.
- Half-life: Parent, metabolite, tissue, and functional half-lives are unknown in humans.
- Accumulation/steady state: Unknown. No one knows whether repeated dosing reaches predictable steady state, binds pigment/tissues, creates active metabolites, or accumulates photoreactive material.
- Near-complete elimination/washout: Unknown. Consequently, no evidence-based sunlight, interaction, cycling, or pre-procedure washout can be supplied.
- Metabolism/elimination: Human CYP, MAO, conjugation, renal/fecal excretion, active metabolites, and photoproducts have not been adequately characterized.
Evidence and Experiences
Evidence is entirely preclinical for efficacy. Cell counts, tyrosine-hydroxylase expression, rodent toxin models, and mitochondrial assays cannot establish improved motivation, reversal of stimulant injury, addiction treatment, or safety in a healthy human. There are no human effect sizes, incidence rates, dose-response curves, or long-term follow-ups.
Forum reports are scarce but not nonexistent. Positive accounts describe mild/gentle motivation, restored reward sensitivity, or gradual relief from stimulant-associated anhedonia. Negative and null accounts include no change after several days, anxiety, sleep disturbance, headache, libido changes, and reports of unusually easy sunburn. Users’ “Dracula” light-avoidance protocols show that the photochemical concern influences behavior; they do not validate a safe UV threshold or washout. Mixed and scarce user experiences · Motivation alongside reported sun sensitivity and libido change · Stimulant-anhedonia account with major confounding · No useful effect after several days · Gradual improvement but no clean attribution
Safety, Interactions, and Monitoring
There is no human adverse-event incidence. Major unresolved domains include phototoxicity/photogenotoxicity, retinal exposure, long-term neurotoxicity, genotoxicity/carcinogenicity, reproductive and developmental toxicity, liver/kidney effects, movement changes, and psychiatric activation. The correct conclusion from missing toxicology is unknown risk, not “no reported deaths.”
Because 9-Me-BC inhibits both MAO isoforms in vitro, combining it with MAOIs, SSRIs/SNRIs, other serotonergic drugs, 5-HTP, stimulants, levodopa, dopamine agonists, dextromethorphan, tramadol, sympathomimetics, or tyramine-rich exposure could be dangerous in principle. No human study tells us whether those classic MAOI interactions occur at forum exposures or how long to separate them. Avoiding a few foods or sunlight does not solve unknown systemic pharmacology.
Stop and obtain medical assessment for a burn/rash or eye symptoms after light, severe headache, marked hypertension, agitation, confusion, hyperthermia, clonus/rigidity, hallucinations, mania, seizure, movement change, jaundice/dark urine, severe abdominal symptoms, or suicidal deterioration. Pulse, blood pressure, sleep, mood, skin/eye symptoms, and objective function could be tracked, but monitoring cannot make an uncharacterized research chemical safe or establish its disappearance.
Human tolerance, dependence, withdrawal, receptor adaptation, cycling, and washout are unknown. Require independent identity, assay, impurity, residual-solvent, heavy-metal, and degradation testing even for research—and recognize that analytical purity still cannot establish human safety. Pregnancy, adolescence, psychiatric illness, cardiovascular disease, photosensitivity, eye disease, and liver/kidney impairment have no established safe-use basis.
Bottom Line
9-Me-BC has one of the most interesting preclinical dopamine stories in this guide and one of the weakest human foundations: zero controlled human efficacy and zero usable human PK. Reports of restored motivation are worth recording as anecdotes, not promoting as regeneration. Unknown metabolism, MAO interactions, and real experimental photochemical warning signals make the self-experimentation risk-benefit unfavorable.
@Volpa #Volpamogs
Last edited:
